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Background: Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months is the standard
adjuvant regimen for patients with high-risk stage II or III colorectal cancer. However, the regimen is
associated with cumulative toxicity, characterised by chronic and often irreversible neuropathy.
Objectives: To assess the efficacy of 3-month versus 6-month adjuvant chemotherapy for colorectal
cancer and to compare the toxicity, health-related quality of life and cost-effectiveness of the durations.
Design: An international, randomised, open-label, non-inferiority, Phase III, parallel-group trial.
Setting: A total of 244 oncology clinics from six countries: UK (England, Scotland, Wales and Northern
Ireland), Denmark, Spain, Sweden, Australia and New Zealand.
Participants: Adults aged ≥ 18 years who had undergone curative resection for high-risk stage II or III
adenocarcinoma of the colon or rectum.
Interventions: The adjuvant treatment regimen was either oxaliplatin and 5-fluorouracil or oxaliplatin and
capecitabine, randomised to be administered over 3 or 6 months.
Main outcome measures: The primary outcome was disease-free survival. Overall survival, adverse
events, neuropathy and health-related quality of life were also assessed. The main cost categories were
chemotherapy treatment and hospitalisation. Cost-effectiveness was assessed through incremental cost
comparisons and quality-adjusted life-year gains between the options and was reported as net monetary
benefit using a willingness-to-pay threshold of £30,000 per quality-adjusted life-year per patient.
Results: Recruitment is closed. In total, 6088 patients were randomised (3044 per group) between
27 March 2008 and 29 November 2013, with 6065 included in the intention-to-treat analyses (3-month
analysis, n = 3035; 6-month analysis, n = 3030). Follow-up for the primary analysis is complete. The 3-year
disease-free survival rate in the 3-month treatment group was 76.7% (standard error 0.8%) and in the
6-month treatment group was 77.1% (standard error 0.8%), equating to a hazard ratio of 1.006 (95%
confidence interval 0.909 to 1.114; p-value for non-inferiority = 0.012), confirming non-inferiority for
3-month adjuvant chemotherapy. Frequent adverse events (alopecia, anaemia, anorexia, diarrhoea,
fatigue, hand–foot syndrome, mucositis, sensory neuropathy, neutropenia, pain, rash, altered taste,
thrombocytopenia and watery eye) showed a significant increase in grade with 6-month duration; the
greatest difference was for sensory neuropathy (grade ≥ 3 was 4% for 3-month vs.16% for 6-month
duration), for which a higher rate of neuropathy was seen for the 6-month treatment group from month
4 to ≥ 5 years (p < 0.001). Quality-of-life scores were better in the 3-month treatment group over months
4–6. A cost-effectiveness analysis showed 3-month treatment to cost £4881 less over the 8-year analysis
period, with an incremental net monetary benefit of £7246 per patient.
Conclusions: The study achieved its primary end point, showing that 3-month oxaliplatin-containing
adjuvant chemotherapy is non-inferior to 6 months of the same regimen; 3-month treatment showed a
better safety profile and cost less. For future work, further follow-up will refine long-term estimates of the
duration effect on disease-free survival and overall survival. The health economic analysis will be updated
to include long-term extrapolation for subgroups. We expect these analyses to be available in 2019–20.
The Short Course Oncology Therapy (SCOT) study translational samples may allow the identification of
patients who would benefit from longer treatment based on the molecular characteristics of their disease.
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Trial registration: Current Controlled Trials ISRCTN59757862 and EudraCT 2007-003957-10.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 64.
See the NIHR Journals Library website for further project information. This research was supported by the
Medical Research Council (transferred to NIHR Evaluation, Trials and Studies Coordinating Centre – Efficacy
and Mechanism Evaluation; grant reference G0601705), the Swedish Cancer Society and Cancer Research
UK Core Clinical Trials Unit Funding (funding reference C6716/A9894).
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EORTC European Organisation for Research
and Treatment of Cancer
EQ-5D EuroQol-5 Dimensions
EQ-5D-3L EuroQol-5 Dimensions,
three-level version
FACT/
GOG-Ntx4
Functional Assessment of Cancer
Therapy/Gynecologic Oncology
Group–Neurotoxicity
HR hazard ratio
HRQoL health-related quality of life
IDEA International Duration Evaluation
of Adjuvant chemotherapy
IQR interquartile range
ITT intention to treat
i.v. intravenous
NCI National Cancer Institute
NIHR National Institute for
Health Research
NMB net monetary benefit
pNI p-value for non-inferiority
PRO patient-reported outcome
QALY quality-adjusted life-year
RCT randomised controlled trial
SCOT Short Course Oncology Therapy
SD standard deviation
SE standard error
ToT time on treatment
ULN upper limit of normal
WTP willingness to pay
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Plain English summary
Patients diagnosed with bowel cancer are likely to have surgery to remove the tumour. Patientsdiagnosed with a more advanced stage of the disease are then likely to be offered what is known as
adjuvant chemotherapy – chemotherapy to kill any cancer cells that have already spread but cannot be
seen. Adjuvant chemotherapy is usually given over 6 months using two medicines known as oxaliplatin
and fluoropyrimidine. This chemotherapy has side effects of diarrhoea, nausea and vomiting, and it
reduces the numbers of cells in the blood. It can also damage nerves, which causes discomfort, numbness
and tingling; in some cases, this can go on for years. These side effects are more likely to develop with
longer treatment. This study looked at whether or not shortening the time over which patients were given
oxaliplatin and fluoropyrimidine chemotherapy reduced its effectiveness.
In this large study of over 6000 patients, half of the patients were allocated by chance to be treated for
3 months and the other half to be treated for 6 months. Reducing the time that patients had chemotherapy
from 6 months to 3 months did not make the treatment less effective. When patients treated with
chemotherapy over 3 months were compared with those treated over 6 months, 77% of patients in both
groups were well with no detectable disease 3 years after surgery. Patients were less likely to get side
effects with 3-month chemotherapy. In particular, the chance of persistent long-term nerve damage was
lower, resulting in patients with 3-month chemotherapy having better health-related quality of life.
Overall, the study showed that 3-month adjuvant chemotherapy for patients with bowel cancer is as
effective as 6-month adjuvant chemotherapy and causes fewer side effects.
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Scientific summary
Background
Patients with high-risk stage II or stage III colorectal cancer usually undergo surgical resection, followed by
6-month adjuvant chemotherapy. Administration of an oxaliplatin and fluoropyrimidine-based adjuvant
chemotherapy regimen improves disease-free survival but is associated with a problematic toxicity profile; in
particular, dose-dependent, cumulative peripheral neuropathy is a key toxicity that can persist long term despite
the treatment for colorectal cancer having been curative. The toxicity of oxaliplatin and fluoropyrimidine
regimens is cumulative, so reducing adjuvant treatment duration could ameliorate such effects; however,
whether or not shortening the duration of adjuvant treatment could compromise its efficacy is debated.
The cost of colorectal cancer treatment in the year after diagnosis is considerably higher than that of
treating other common cancers. Three-month adjuvant chemotherapy could be anticipated to be more
cost-effective than the current standard 6-month treatment, provided that efficacy is maintained.
The Short Course Oncology Therapy (SCOT) study was designed to compare 3-month and 6-month
oxaliplatin-based adjuvant chemotherapy in patients with colorectal cancer in terms of efficacy, toxicity,
health-related quality of life and economic aspects.
Objectives
The objectives of the study were to assess the efficacy of 3-month versus 6-month adjuvant chemotherapy
for colorectal cancer and to compare the associated toxicity and health-related quality of life. The primary
end point of the study was disease-free survival, with the null hypothesis being that 3-month chemotherapy
is inferior to 6-month chemotherapy with a hazard ratio of > 1.13. Secondary end points were overall
survival, safety, health-related quality of life and cost-effectiveness parameters.
The economic evaluation explored the cost-effectiveness of 3-month versus 6-month adjuvant chemotherapy
(in terms of incremental cost, quality-adjusted life-year gains and net monetary benefit with a willingness-to-
pay threshold of £30,000/quality-adjusted life-year), using trial data on treatment and hospitalisation costs,
health-related quality of life, and survival outcomes within the timeframe of the SCOT clinical trial.
Methods
The SCOT trial was an international, randomised (1 : 1), open-label (non-blinded), non-inferiority, Phase III,
parallel-group trial comparing 3 months with 6 months of oxaliplatin plus fluoropyrimidine adjuvant
chemotherapy in patients with high-risk stage II or stage III colorectal cancer. The study was conducted in
244 oncology clinics in six countries (the UK, Denmark, Spain, Sweden, Australia and New Zealand).
Eligible patients were adults aged ≥ 18 years who had undergone curative resection for high-risk stage II
(having one or more of the following risk features: T4 disease, tumour obstruction and/or perforation of
the primary tumour, < 10 lymph nodes harvested, poorly differentiated histology, perineural invasion or
extramural venous/lymphatic vascular invasion) or stage III adenocarcinoma of the colon or the rectum.
DOI: 10.3310/hta23640 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 64
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Iveson et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi
Patients were randomised (one to one) to receive either 3 months or 6 months of treatment using a
minimisation algorithm incorporating a random component. Minimisation factors were study centre,
treatment regimen, sex, disease site (colon or rectum), N stage (X, 0, 1 or 2), T stage (X, 0, 1, 2, 3 or 4),
and capecitabine starting dose (for those receiving oxaliplatin and capecitabine). The adjuvant treatment
regimen used could be oxaliplatin with 5-fluorouracil or oxaliplatin with capecitabine, with the treatment
selected on an individual-patient basis to reflect the choice of the patient and/or physician.
Disease-free survival was defined as the time from randomisation (or trial registration for those randomised
after 3 months of therapy) to relapse, development of a new colorectal cancer, or death from any cause.
Overall survival was defined as the time from randomisation (or registration for those randomised at
3 months) to death from any cause. Comparison of disease-free survival between treatment groups was
based on a Cox regression model incorporating minimisation factors as covariates; the population selection
was intention to treat.
Toxicity was assessed by the investigators after each cycle of chemotherapy, with adverse events graded
using the National Cancer Institute common terminology criteria for adverse events (version 3). Patients
were followed up for a minimum of 3 years to a maximum of 8 years. Health-related quality of life was
assessed using the European Organisation for Research and Treatment of Cancer questionnaires QLQ-C30
and QLQ-CR29, and using EuroQol-5 Dimensions, three-level version. Neuropathy was assessed with the
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity (FACT/GOG-Ntx4)
questionnaire.
The economic analysis was undertaken from the perspective of the UK NHS and Personal Social Services
for 2016. The effectiveness measure for the economic analysis was the discounted quality-adjusted life-
year gain per patient. Overall survival data were partitioned into three health states, (1) time on treatment,
(2) disease free and (3) recurrence, with Kaplan–Meier sample averages used to compute the quality-
adjusted survival time in each health state over the 8-year within-trial period; a separate model estimated
health-related quality of life for each health state. Costs associated with patient treatment were calculated
by measuring and valuing resources used by patients during the treatment and follow-up periods. The
total cost of treatment per patient was estimated as the Kaplan–Meier survival analysis, considering the
main cost categories of chemotherapy treatment and hospitalisation. Bootstrapping was used to account
for uncertainty of the results and probabilistic sensitivity analysis was reported through confidence intervals
and cost-effectiveness acceptability curves.
Results
A total of 6088 patients from 244 centres were randomised into the trial between 27 March 2008 and
29 November 2013: 5244 patients were randomised at 164 study centres in the UK, 311 patients were
randomised at 10 centres in Denmark, 237 patients were randomised at 19 centres in Spain, 197 patients
were randomised at 32 centres in Australia, 83 patients were randomised at 14 centres in Sweden and
16 patients were randomised at five centres in New Zealand. Of these, 6065 patients were included in the
intention-to-treat analysis population and 6022 patients started study treatment. Data cut-off point for the
analyses was 1 December 2016, at which time patients in both treatment groups had reached a median
follow-up of 37 months.
Baseline data identified approximately 60% of patients as male and 40% as female, with the median
age being 65 years. Most patients (> 80%) had a diagnosis of colon cancer and approximately 80% had
stage III disease. For about 67% of patients, the planned treatment comprised oxaliplatin and capecitabine,
with the remaining 33% of patients planned to receive oxaliplatin and 5-fluorouracil. Baseline characteristics
were comparable for the 3-month and 6-month treatment groups.
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Overall, 83.3% of patients randomised to the 3-month treatment group received 3 months of treatment
and 58.8% of those randomised to the 6-month treatment group received 6 months of treatment; 6.9%
of patients randomised to the 6-month treatment group stopped treatment at 3 months. The most
common reason for not completing 6 months of treatment was an inability to tolerate the associated
toxicity. The median percentage of the full fluoropyrimidine dose delivered was 95.3% for the 3-month
and 83.2% for the 6-month treatment group; the median percentage of the full oxaliplatin dose delivered
was 96.6% for the 3-month and 70.2% for the 6-month treatment group.
By the time of analysis, there were 1482 disease-free survival events (740 in the 3-month treatment group
and 742 in the 6-month treatment group). The 3-year disease-free survival rate was 76.7% (standard error
0.8%) for the 3-month treatment group and was 77.1% (standard error 0.8%) for the 6-month treatment
group; this equated to a hazard ratio of 1.006 (95% confidence interval 0.909 to 1.114; p-value for
non-inferiority = 0.012). The study, therefore, confirmed non-inferiority for 3-month versus 6-month
oxaliplatin-based adjuvant chemotherapy. By the time of analysis, there were 787 deaths, with the 3-year
overall survival rate for the 3-month treatment group being 90.0% (standard error 0.6%) and for the
6-month treatment group 89.6% (standard error 0.6%), equating to a hazard ratio of 0.994 (95%
confidence interval 0.964 to 1.143; p-value for non-inferiority = 0.035).
Treatment safety/toxicity was assessed for 868 patients. The most common adverse events seen during
the study were alopecia, anaemia, anorexia, diarrhoea, fatigue, hand–foot syndrome, mucositis, sensory
neuropathy, neutropenia, pain, rash, altered taste, thrombocytopenia and watery eye; these adverse
events showed a statistically significant increase in severity for the 6-month treatment group compared with
the 3-month treatment group. Sensory neuropathy, diarrhoea, neutropenia, fatigue, pain, nausea and
hand–foot syndrome were the most common grade ≥ 3 adverse events reported, with statistically significant
differences observed between treatment groups for diarrhoea (p = 0.033), neutropenia (p = 0.023), pain
(p = 0.014), hand–foot syndrome (p = 0.031) and sensory neuropathy (p < 0.001). The most marked increase
in the proportion of patients with grade ≥ 3 with 6-month adjuvant chemotherapy was for sensory
neuropathy (16.4% vs. 4.3% with 3-month treatment). Serious adverse reactions were reported for
421 patients in the 3-month treatment group and for 511 patients in the 6-month treatment group.
Thirty-two patients died as a result of events attributed to treatment toxicity, with the events distributed
equally between the randomised groups (16 patient deaths for both the 3-month and the 6-month
treatment groups).
Peripheral neuropathy was also assessed using the FACT/GOG-Ntx4 questionnaire, with data available for
2871 patients who were assessed for up to 7 years. The neurotoxicity standardised adjusted area under
the curves for questionnaire scores differed markedly between treatment groups (p < 0.001), with a higher
rate of neuropathy for the 6-month treatment group being apparent from 4 months and persisting to
≥ 5 years (p < 0.001).
Health-related quality of life was assessed using the European Organisation for Research and Treatment
of Cancer QLQ-C30 and CR29 (n = 1829) and EuroQol-5 Dimensions, three-level version (n = 1828) and
the area under the curves was compared. European Organisation for Research and Treatment of Cancer
QLQ-C30 global health status and functional and symptom scales demonstrated a statistically significant
difference between treatment groups. Scores for the two groups mirrored each other for the first 3 months
of treatment but subsequently showed functional improvement and decreased side effects in those who
stopped treatment at 3 months. The largest difference between the treatment groups was seen at 6 months
and, thereafter, mean values became more comparable as patients completed 6 months of treatment. For
the European Organisation for Research and Treatment of Cancer QLQ-CR30, a subset of symptoms showed
statistically significant differences, indicating fewer side effects in patients who received 3-month adjuvant
chemotherapy (body image, p = 0.037; dry mouth, p < 0.001; hair loss, p = 0.035; taste alteration,
p < 0.0001). The magnitude of the mean differences in functional and global health status scales between
treatment groups was indicative of ’moderate’ differences in global health status, role functioning and social
function and ’a little’ difference in physical, emotional and cognitive functions. Statistically significant
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differences in area under the curves between the treatment groups were also seen for both the EuroQol-5
Dimensions self-rated visual analogue scale (p = 0.00081) and the EuroQol-5 Dimensions, three-level version
health index (p = 0.00081), with differences apparent from months 4 to 6.
Adjuvant chemotherapy costs were higher for the 6-month treatment group (p < 0.001) and hospitalisation
costs differed between treatment groups from 4 to 6 months after the start of treatment (p < 0.001).
However, 6-month adjuvant chemotherapy was also associated with higher hospitalisation costs over the
7- to 12-month period (p = 0.030), possibly reflecting the persistence of treatment-related complications.
No difference in cost was seen between the treatment groups after 12 months. Overall, the cost was
significantly higher for the 6-month treatment group (p < 0.001), driven primarily by hospitalisation
(–£2835) rather than the by cost of the adjuvant chemotherapy agents (–£1829). The 3-month treatment
strategy was dominant, as it was cost saving and showed an improvement in quality-adjusted life-years,
with an incremental net monetary benefit of £7246 per patient. Three-month adjuvant chemotherapy for
colorectal cancer showed 99% probability of being cost-effective across the UK decision threshold range
of £20,000–30,000 per quality-adjusted life-year.
Conclusions
The SCOT study showed that the efficacy of 3 months of oxaliplatin-containing adjuvant chemotherapy is
non-inferior to 6 months of the same regimen; 6-month treatment was also associated with considerably
higher levels of toxicity, particularly neurotoxicity, which can be chronic. Compared with traditional
6-month adjuvant chemotherapy, the 3-month treatment strategy costs significantly less and has no
significant detrimental impact on patient outcomes (health-related quality of life and survival). Three-month
oxaliplatin-based chemotherapy should, therefore, be considered as an option as adjuvant therapy for
patients with high-risk stage II or stage III colorectal cancer, particularly when using oxaliplatin and
capecitabine combination therapy.
Recommendations for research
The SCOT trial raised questions regarding whether 3-month treatment is applicable when using oxaliplatin and
5-fluorouracil as the adjuvant regimen or when treating patients with high-risk disease (T4 or N2 pathology).
Further research should be conducted to identify any specific patient groups (e.g. patients with specific high-
risk pathological features) for whom 6 months of adjuvant chemotherapy might be appropriate and if this is
dependent on the regimen selected. The translational tissue samples from the SCOT study (3383 tumour
samples and 3100 blood samples) and other similar studies should be used to build molecular predictors of
which patients may benefit from a longer treatment duration. Some of this work is currently underway for the
SCOT study.
Trial registration
This trial is registered as ISRCTN23516549 and EudraCT 2007-003957-10.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research (NIHR). This research was supported by the Medical Research Council
(transferred to NIHR Evaluation, Trials and Studies Coordinating Centre – Efficacy and Mechanism
Evaluation; grant reference G0601705), the Swedish Cancer Society and Cancer Research UK Core Clinical
Trials Unit Funding (funding reference C6716/A9894).
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Chapter 1 Introduction
Colorectal cancer is a common malignancy, with 1,360,000 cases annually, leading to 694,000 deathseach year. Colorectal cancer accounts for 12% of all new cancer cases each year in the UK, with
approximately 41,265 cases estimated in 2014.1 The initial treatment for patients presenting with
colorectal cancer is usually surgical resection, which is potentially curative; however, 40–50% of patients
subsequently relapse and die as a result of the disease becoming metastatic.2 Postoperative adjuvant
fluoropyrimidine-based chemotherapy was first shown to reduce the recurrence of colon cancer in 1990.3
Initially, adjuvant treatment was given for 12 months, but a randomised study suggested equivalence for
6 months of treatment,4 which is now accepted as the standard duration for adjuvant chemotherapy in
patients with high-risk stage II or stage III colorectal cancer.5
High-risk stage II is defined as having one of the following risk features: T4 disease, tumour obstruction
and/or perforation, < 10 lymph nodes harvested, poorly differentiated histology, perineural invasion or
extramural venous/lymphatic vascular invasion.
The addition of oxaliplatin to a fluoropyrimidine-based regimen has been shown to improve 3-year disease-
free survival (DFS) in patients with colorectal cancer.6–8 The benefit seen in the MOSAIC6 and NSABP C-077
studies was similar, despite the total oxaliplatin doses being different (1020 mg/m2 and 765 mg/m2,
respectively).6,7 These studies led to the adoption of oxaliplatin and fluoropyrimidine chemotherapy as
the adjuvant treatment of choice for most patients with stage III disease who were aged < 70 years.5,9
However, the administration of oxaliplatin with the fluoropyrimidine backbone results in additional toxicity,
with increased neutropenia, thrombocytopenia, diarrhoea, nausea and vomiting.6,7 There is also increased
peripheral neuropathy, which is cumulative, dose-dependent and often irreversible, persisting long term
despite the treatment of colorectal cancer having been curative. Neurotoxicity was measured using the
National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) (version 1) in MOSAIC
study,6 and the NCI-Sanofi Neurosensory score in the NSABP C-07 study.7 In the MOSAIC trial, 12.4% of
patients experienced grade 3 sensory neuropathy, with 0.5% having residual problems at 18 months;6 in the
NSABP C-07 trial, 8.4% of patients had grade 3 or 4 neuropathy at the end of treatment, with 10% reporting
some residual neuropathy beyond 2 years.10
As the toxicity of oxaliplatin and fluoropyrimidine regimens is cumulative, a reduction in the duration of
adjuvant treatment could potentially ameliorate such effects;11 however, whether or not short-duration adjuvant
treatment could compromise efficacy is widely debated. Data for one study12 are available in the literature,
comparing 3 months with 6 months of adjuvant treatment with a fluoropyrimidine-based chemotherapy
regimen; however, the study was conducted before the introduction of oxaliplatin-combination adjuvant
treatment. Although the study was somewhat underpowered, reducing treatment duration did not appear to
affect patient outcomes and was associated with reduced toxicity and improved health-related quality of
life (HRQoL).
The cost of treatment for colorectal cancer in the first year after diagnosis is considerably higher than
that of treating other common cancers and was estimated to cost the English health-care system £542M
in 2010.13 Three-month duration adjuvant chemotherapy for patients with colorectal cancer could be
anticipated to be more cost-effective than the current standard 6-month duration, provided that efficacy
is maintained. Benefits might be associated not only with lower treatment costs but also with reduced
expenditure to manage problematic side effects and improvements in HRQoL.
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The Short Course Oncology Therapy (SCOT) study was designed to compare 3-month and 6-month
oxaliplatin-based adjuvant chemotherapy in patients with colorectal cancer in terms of efficacy, toxicity,
HRQoL and economic aspects. At the time of starting this study, no published data were available on the
effectiveness of short-duration treatment with adjuvant oxaliplatin and fluoropyrimidine regimens in
patients with colorectal cancer. The main objective of the study was to identify whether or not 3-month
adjuvant chemotherapy was inferior to 6-month treatment in terms of DFS rate. The trial also aimed to
compare overall survival, toxicity and HRQoL in patients between the two treatment groups and to assess
the cost-effectiveness of the two regimens. The SCOT study was designed as an international, stand-alone
study of adjuvant oxaliplatin and fluoropyrimidine treatment conducted in patients with high-risk stage II
or stage III colon or rectal cancers. Although stand-alone, the SCOT study was conducted in parallel with
the International Duration Evaluation of Adjuvant chemotherapy (IDEA) collaborative initiative, which aimed
to consolidate results from numerous worldwide trials that were attempting to clarify the importance of
adjuvant treatment duration for colon cancer patients. The IDEA initiative was restricted to treatment of
patients with stage III colon cancer; therefore, it was prospectively planned that patient data from the SCOT
study would be pooled with those from six other studies (TOSCA, IDEA France, CALGB/SWOG 80702,
ACHIEVE and HORG).14
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Chapter 2 Methods
Study design
The SCOT study was an international, randomised (1 : 1), open-label (non-blinded), non-inferiority, Phase III,
parallel-group trial comparing 6 months with 3 months of oxaliplatin plus fluoropyrimidine adjuvant
chemotherapy in patients with high-risk stage II or stage III colorectal cancer.
The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice
guidelines;15 all aspects of the study received ethics approval from the ethics services in the participating
countries. All participants provided written informed consent before enrolment.
Study participants
Parts of this section are taken from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an
Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Patients were recruited from 244 oncology clinics from six countries (the UK, Denmark, Spain, Sweden,
Australia and New Zealand).
Eligible patients were adults aged ≥ 18 years who had undergone curative resection for high-risk stage II
(having one or more of the following risk features: T4 disease, tumour obstruction and/or perforation of
the primary tumour, < 10 lymph nodes harvested, poorly differentiated histology, perineural invasion or
extramural venous/lymphatic vascular invasion) or stage III adenocarcinoma of the colon or rectum.
Patients were enrolled within 11 weeks of surgery and started treatment in their allocated treatment group
within 2 weeks of randomisation. Other eligibility inclusion requirements included having a World Health
Organization performance status of 0 or 1, having adequate organ function and having a life expectancy
of > 5 years with reference to non-cancer-related disease, accepting that they may die earlier due to
colorectal cancer. Patients were to have a normal computed tomography scan of the chest, abdomen and
pelvis prior to study enrolment and a carcinoembryonic antigen level of < 1.2 times the local upper limit
of normal (ULN) in the week prior to randomisation. Rectal cancer patients were to have undergone total
mesorectal excision with negative resection margins (> 1 mm clearance).
Exclusion criteria included undergoing chemotherapy (except chemotherapy administered with curative
intent that had been completed > 5 years previously with no residual complications); having undergone
previous long-course chemoradiotherapy (preoperative short-course radiotherapy was allowed); having
moderate or severe renal impairment (creatinine clearance rate of < 30 ml/minute using the Cockcroft–Gault
equation); having a haemoglobin concentration of < 9 g/dl, an absolute neutrophil count of < 1.5 × 109
per litre, a platelet count of < 100 × 109 per litre, and aspartate aminotransferase or alanine aminotransferase
levels of > 2.5 × ULN; having clinically significant cardiovascular disease; being pregnant or lactating; being
of childbearing potential and not using or being unwilling to use medically approved contraception
(postmenopausal women were to have been amenorrhoeic for ≥ 12 months to be considered of non-
childbearing potential); having previous malignancy other than adequately treated in situ carcinoma of the
uterine cervix or basal or squamous cell carcinoma of the skin (unless there was a disease-free interval of
≥ 5 years); and having known or suspected dihydropyrimidine dehydrogenase deficiency.
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Public/patient involvement
The original SCOT study protocol was formally reviewed by consumers as part of the internal review and
approval processes at the Glasgow Clinical Trials Unit. Patients were involved informally in the original
concept of the trial, and they thought that whether or not shorter chemotherapy could reap the same
benefit as longer chemotherapy was an exceptionally important question to define.
Patients at the clinics of the lead investigators were also asked about a proposal to extend study follow-up
to increase the number of DFS events for analysis (application to the NIHR programme in 2014). As they
felt that the question was exceptionally important, the view was that every effort should be made to
extend the study to ensure that a thorough and accurate answer could be obtained for both patients with
low-risk and patients with high-risk disease. The proposal to extend the study was also formally discussed
and supported both by the main National Cancer Research Institute Colorectal Clinical Studies group and
at the meeting of the Adjuvant and Advanced Disease subgroups. The public/patient representative at
these meetings was fully supportive.
Study interventions
Parts of this section are taken from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an
Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
The adjuvant treatment regimen used was oxaliplatin with 5-fluorouracil (5FU) or oxaliplatin with
capecitabine. Participating sites were able to select which treatment combination they wanted to use
on an individual-patient basis, reflecting the choice of the patient and/or physician.
Oxaliplatin and 5-fluorouracil
For patients receiving oxaliplatin and 5FU, treatment was given every 2 weeks, the intention being to
deliver six cycles to patients assigned 3 months of therapy and 12 cycles to patients assigned 6 months of
therapy. On the first day of each cycle, 85 mg/m2 of intravenous (i.v.) oxaliplatin was given over 2 hours,
concurrently with 175 mg of L-folinic acid or 350 mg of folinic acid (also known as leucovorin). This was
followed by a 400 mg/m2 5FU i.v. bolus injection administered over 5 minutes, and then a continuous i.v.
infusion of 2400 mg/m2 of 5FU over 46 hours. At the investigator’s discretion, patients who were aged
> 70 years could start both 5FU infusions at 75% of the specified starting dose, if clinically indicated.
If a grade 1 adverse event (AE) occurred as a result of chemotherapy, treatment was to be continued at
the full dose. For treatment-related AEs of grade ≥ 2, treatment was to be withheld until recovery to
grade 1 and then restarted. If more than one delay or a delay of ≥ 2 weeks occurred, doses of oxaliplatin
and infused 5FU were to be kept the same but the bolus 5FU dose was to be omitted; if further delays
occurred as a result of myelotoxicity, the oxaliplatin and infusional 5FU doses were to be reduced by 25%.
In addition, if after the first cycle the neutrophil count was < 1.0 × 109 cells/l, the bolus 5FU dose was to be
omitted and the oxaliplatin and infused 5FU doses were to be reduced by 25%. Wherever possible, the
oxaliplatin dose was to be reduced rather than discontinued; if oxaliplatin dosing had to be discontinued,
5FU was to be continued where possible.
Oxaliplatin and capecitabine
For patients receiving oxaliplatin and capecitabine, treatment was given every 3 weeks, the intention being
to deliver four cycles to patients assigned 3 months of therapy and eight cycles to patients assigned
6 months of therapy. On the first day of each cycle, 130 mg/m2 of i.v. oxaliplatin was given over 2 hours.
Oral capecitabine 1000 mg/m2 was taken twice per day for the first 14 days of each cycle. Patients with a
creatinine clearance rate of 30–50 ml/minute were to start capecitabine treatment at 75% of the specified
dose. Patients aged > 70 years could be considered for treatment with capecitabine at 75% of the full
dose, with the decision to reduce dose being made at the discretion of the investigator depending on the
fitness of the individual patient. If the investigator considered that any patient required dose reduction
METHODS
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because of any other comorbidity, the patient could receive a minimum starting dose of oral capecitabine
of 800 mg/m2 twice per day.
If a grade 1 AE occurred as a result of chemotherapy, treatment was to be continued at the full dose.
For treatment-related AEs of grade ≥ 2, treatment was to be withheld until recovery to grade 1 and then
restarted. For AEs related to oxaliplatin and capecitabine, if more than one delay or a delay of ≥ 2 weeks
occurred, capecitabine and oxaliplatin doses were to be reduced by 25%; if further delays occurred as a
result of myelotoxicity, further dose reductions were allowed at the investigator’s discretion.
Objectives
The objective of the SCOT study was to assess the efficacy of 3-month versus 6-month adjuvant
chemotherapy for colorectal cancer and to compare the associated toxicity and HRQoL. The study also
provided data for an economic analysis of the cost-effectiveness of the two regimens. The primary end
point of the study was DFS, the null hypothesis being that 3-month chemotherapy is inferior to 6-month
chemotherapy with a hazard ratio (HR) of > 1.13. Secondary end points were overall survival, safety,
HRQoL and cost-effectiveness parameters.
The aim of the economic evaluation was to explore the cost-effectiveness of 3-month versus 6-month
adjuvant chemotherapy [in terms of incremental cost per quality-adjusted life-year (QALY) gains and net
monetary benefit (NMB)], using trial data on treatment and hospitalisations costs, HRQoL and survival
outcomes within the timeframe of the SCOT clinical trial.
Outcomes
Parts of this section are taken from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an
Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Disease-free survival was defined as the time from randomisation (or from trial registration for those randomised
after 3 months of therapy) to relapse, development of a new colorectal cancer, or death from any cause. Overall
survival was defined as the time from randomisation (or registration for those randomised at 3 months) to death
from any cause. Toxicity was assessed by the investigators after each cycle of chemotherapy with AEs graded
using NCI CTCAE version 3.
Patients were followed up for a minimum of 3 years to a maximum of 8 years, with full blood count, urea
and electrolyte levels, liver function and carcinoembryonic antigen all being tested at 9, 12, 18, 24 and
36 months, and then annually. Computed tomography of the chest, abdomen and pelvis was conducted
at 6, 12, 18, 24 and 36 months.
Health-related quality of life was assessed using the European Organisation for Research and Treatment
of Cancer (EORTC) questionnaires QLQ-C3017 and QLQ-CR29,18 and using the EuroQol-5 Dimensions,
three-level version (EQ-5D-3L) (with both the visual analogue scale and the health index),19 with UK value
sets.20 Neuropathy was assessed using the Functional Assessment of Cancer Therapy/Gynecologic Oncology
Group–Neurotoxicity (FACT/GOG-Ntx4) questionnaire.21 Questionnaires were administered at baseline and
before each treatment cycle. Additionally, HRQoL was assessed each month in the first 3 months after
treatment for the 3-month treatment group. Subsequent assessments were conducted at 9 and 12 months
for the EORTC questionnaires; 9, 12, 18 and 24 months and then annually for the EQ-5D-3L; and up to
12 months for the FACT/GOG-Ntx4.
Sample size
Parts of this section are taken from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an
Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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In the previous MOSAIC trial, 3-year DFS in the oxaliplatin and 5FU treatment group was 78% compared
with 73% for 5FU plus leucovorin.6 To be able to conclude that the 3-month treatment group in the SCOT
study was non-inferior, it was assumed that at least half of this benefit should be retained.
The SCOT study was designed as a randomised (1 : 1) non-inferiority trial aiming to reliably determine
whether or not there was < 2.5% decrease in the 3-year DFS for patients in the 3-month treatment group
(from 78% in the 6-month treatment group), which corresponds to excluding a HR of > 1.13 with 90%
power at the 2.5%, one-sided level of significance. Assuming that the study would recruit over a period of
5 years with a subsequent minimum follow-up of 2 years, this design required 8600 patients to undergo
randomisation and 2750 events (relapses, deaths or new colorectal cancers) to be observed; to allow for
loss to follow-up, the recruitment target was 9500 patients.
From the outset, it was recognised that detecting meaningful differences based on safety and HRQoL data
would not require information from all of the 9500 planned patients. For safety outcomes, 700 patients
(350 in each group) were deemed sufficient to detect (80% power and a 2-sided significance level of 5%)
a halving in the proportion of patients with grade 3 or 4 toxic effects from 12% to 6% (12% being the
rate at which grade 3 or 4 paraesthesia, the most common non-haematological grade 3 or 4 toxic effect,
occurred in the oxaliplatin treatment group in the MOSAIC trial).6 This sample size would allow small
changes in global HRQoL to be detected (assuming a difference of magnitude of 7.5322 and a standard
deviation of 23.4)17 with 95% power at the 1% significance level. This more stringent level of significance
was used to allow for multiple testing across various health-related quality-of-life scales. It should be noted
that the power and sample size calculations for safety and health-related quality-of-life outcomes are
based on a superiority comparisons, not on non-equivalence.
All sample size calculations were made in EAST 5.3.0.0 (Cytel Corporation, Cambridge, MA, USA).
Information on toxicity and health-related quality-of-life end points was collected from recruited patients
until the number required was exceeded and the decision to stop was endorsed by the independent data
monitoring committee (DMC) and trial steering committee. An administrative delay in notifying sites about
the end of collection of detailed toxicity information resulted in data being collected from 868 patients. The
DMC had access to summary plots of EORTC HRQoL data, EuroQol-5 Dimensions (EQ-5D) health status data
and FACT/GOG-Ntx4 neuropathy data. In May 2010 (based on interim data from 1047 randomised patients),
the committee recommended that the collection of HRQoL data and FACT/GOG-Ntx4 data should be
continued because they were concerned that the number of missing data might undermine comparison at
later time points. They also recommended that collection of FACT/GOG-Ntx4 data should be extended
beyond 12 months for new patients and, where possible, for patients already participating in the study. In
November 2010, the DMC recommended that the collection of these data should stop once 1800 patients
had been recruited; delays in the amendment of the protocol led to patient recruitment beyond this
recommendation. These extensions to data collection were made to compensate for missing data and were
not based on formal power calculations.
Randomisation
The adjuvant treatment (oxaliplatin and 5FU or oxaliplatin and capecitabine) that was administered was
selected on an individual-patient basis and was not randomised. Patients were randomised (1 : 1) centrally
to receive either 3 months or 6 months of treatment using a minimisation algorithm incorporating a
random component (80% probability of allocation to the ‘minimum’ group; 1 : 1 randomisation if no
preferred group). Minimisation factors were study centre, treatment regimen, sex, disease site (colon or
rectum), N stage (X, 0, 1 or 2), T stage (X, 0, 1, 2, 3 or 4) and capecitabine starting dose (from February
2010 for those receiving oxaliplatin and capecitabine). Centralised randomisation was conducted by the
Cancer Research UK Clinical Trials Unit (Glasgow, UK). The computerised randomisation system allocated
every patient a unique identification number and determined their treatment duration.
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Initially, some participating centres were randomly allocated such that patients would be registered in the
study prior to starting treatment but then be randomised after completing the first 3 months of treatment
(delayed randomisation) to either receive a further 3 months of treatment or stop treatment. The remaining
centres randomised patients to 3 months or 6 months of treatment prior to starting treatment. This delayed
randomisation approach was discontinued because of a poorer randomisation rate [median 4.09, interquartile
range (IQR) 1.29–7.09; n = 41, patients/centre/year] than in centres that randomised patients before the start
of treatment (median 5.21, IQR 3.56–11.55; n = 36).24
The study was open-label for patients, clinicians, and those conducting data analysis.
Statistical analyses
Parts of this section are taken from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an
Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Efficacy and safety analyses
The efficacy analyses of DFS and overall survival included, as far as possible, all randomly assigned patients
[the intention-to-treat (ITT) population] and were plotted using Kaplan–Meier techniques. Analysis of
treatment delivery and safety was based on patients who started the study treatment. The analysis time
was prespecified in the study protocol. Statistical analyses used SPSS version 22 (IBM Corporation, Armonk,
NY, USA) and R version 3.1.2 (The R Foundation for Statistical Computing, Vienna, Austria). The data
cut-off point for this analysis was 1 December 2016.
Comparison of disease-free and overall survival between treatment groups was based on a Cox regression
model incorporating minimisation factors as covariates; this approach was also used to derive the HR and
associated 95% confidence intervals (CIs). The p-value for testing the null hypothesis, that the HR comparing
3 months with 6 months of adjuvant treatment was ≥ 1.13, was derived from this model by comparing the
log-likelihood of the fitted model with the log-likelihood of a model where the HR between groups was set
to 1.13 using a likelihood-ratio test. The proportional hazards assumption implicit in these analyses was
examined graphically using a log-minus log plot of survival function against log time and using a test of the
interaction between treatment group and time (logged) obtained from a Cox model incorporating an
appropriate time-varying covariate.
The components of the forest plot (estimated hazard for the comparison between groups and associated
95% CI) were derived from a Cox model that included separate terms for the effect of duration in each
category of the relevant stratification factor or other factors being examined. The p-value for heterogeneity
was derived from comparison of the log-likelihoods of a model with separate terms for the effect of
duration in each category compared with the model with a single overall term. The aim of this analysis was
to establish whether or not the impact of treatment duration varied across important patient subgroups.
Multiple imputation analysis25 was used to fill in missing data for questionnaires in the HRQoL and
neuropathy scales. Five multiple imputation sets were produced for each HRQoL or neuropathy scale and
the area under the curve (AUC)26 was calculated with imputed data, as prespecified in the statistical
analysis plan. The AUC was then adjusted by dividing by the follow-up period and subtracting the baseline
value for each patient to produce a standardised-adjusted AUC. The standardised-adjusted AUC was
calculated for the five imputed data sets and compared between the randomised treatment groups via a
generalised linear model (with treatment group as an independent factor and study minimisation factors
as covariates). The test statistics associated with treatment group from each of the five imputations were
finally combined to provide an overall p-value that took into account the extent of missing data. To allow
for the number of scales being examined, an adjustment for multiple comparisons (separately for the
EORTC and the EQ-5D questionnaires) was made using the sharpened Hochberg procedure;27 the p-value
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threshold for statistical significance was 5% after adjustment. Comparison of these scales at individual
time points also made use of multiple imputation and generalised linear models.
The Mann–Whitney U-test was used to compare ordered categorical variables for toxicity grade. Fisher’s
exact test was used to compare the incidence of grade 3–5 toxicity and logistic regression was used to
estimate the odds ratio and associated CI for the incidence of grade 3–5 toxicity.
Study data were reviewed by the DMC approximately once a year to assess safety and efficacy issues from
an ethics viewpoint. Conditional power methods28 were used to aid the committee in reaching decisions
about study continuation, but no formal stopping rules were set. The conditional power for DFS was
presented at the fifth (June 2012), sixth (January 2013) and seventh (October 2013) meetings of the DMC;
the DMC requested the analysis because of apparent differences in DFS curves. The results were discussed
by the DMC in the context of the limited follow-up of patients and available survival data. The DMC
concluded that no action was required.
Changes to the study protocol
The approach of randomising patients to a treatment group was changed after the trial had been running
for 1 year; after this time all patients were randomised as they started adjuvant therapy (rather than some
being randomised after 3 months of adjuvant chemotherapy), as this approach proved to have a higher
randomisation rate and a lower dropout rate.
From March 2012, the requirement for the neuropathy questionnaire to be completed was extended to
follow-up visits at 18 and 24 months; from December 2012 the neuropathy questionnaire was to be
completed at follow-up visits to a maximum of 8 years. These extensions to data collection were made
to compensate for missing data and to monitor long-term change in neuropathy.
The planned duration of patient follow-up for the primary analysis was extended so that (1) patients with
stage III disease were to be followed up until the end November 2014 or for a minimum of 3 years (if they
did not have ≥ 3 years of follow-up at the end of November 2014) and (2) all patients with stage II disease
were to be followed up until the end of November 2016. Follow-up was extended to increase the number
of events for the primary study analysis.
METHODS
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Chapter 3 Results
Participant recruitment and flow
The data cut-off point for the analyses presented here was 1 December 2016, at which time patients in
both treatment groups had undergone median follow-up of 37 months (IQR 36–49 months, as calculated
using the reverse Kaplan–Meier approach). A total of 88% of patients were followed up for a minimum of
3 years, which allowed for a 2-month window around the follow-up time. A total of 787 patients had died
by the time of analysis. Study patients are still undergoing follow-up to support further DFS and overall
survival analyses.
A total of 6088 patients were randomised to the trial between 27 March 2008 and 29 November 2013
from 244 centres: 5244 patients were randomised at 164 study centres in the UK, 311 patients at
10 centres in Denmark, 237 patients at 19 centres in Spain, 197 patients at 32 centres in Australia, 83 patients
at 14 centres in Sweden, and 16 patients at five centres in New Zealand. The study did not meet its target of
9500 patients as a result of slow recruitment; despite extending the planned enrolment period by 6 months,
the target was not reached and recruitment was stopped to allow adequate follow-up of ongoing
randomised patients within the budget for the trial. This allowed the minimum follow-up period to be
extended to 3 years. A total of 1482 DFS events were observed, which gave the study 66% power rather
than the planned 90% power for rejecting the null hypothesis.
A total of 6065 patients were included in the ITT analysis population, 6022 of whom started study
treatment. Treatment safety/toxicity was assessed after each chemotherapy cycle for 868 patients. HRQoL
was assessed using EORTC QLQ-C30 and CR29 (n = 1829) and EQ-5D-3L (n = 1828) and neuropathy were
assessed using FACT/GOG-Ntx4 (n = 2871).
The Consolidated Standards of Reporting Trials (CONSORT) flow diagram (Figure 1) shows patients who
entered and progressed through the trial and provided data for the different assessment parameters.
Of the 6088 patients entering the trial, 3044 were randomised into each treatment group (3-month and
6-month duration). Of these 3044 patients, 3035 (99.7% of 3044 randomised to this group) in the
3-month treatment group were included in the ITT analyses, with 3009 patients receiving the study drug,
and 3030 (99.5% of 3044 randomised to this group) in the 6-month treatment group were included in
the ITT analyses, with 3013 patients receiving the study drug. The reasons patients were not included
in the ITT analysis and did not start study treatment are also detailed in Figure 1.
Baseline data
Baseline data (recorded at the time of randomisation) identified approximately 60% of patients as male
and 40% as female, with the median age being 65 years. Most patients (> 80%) had a diagnosis of colon
cancer and approximately 80% had stage III disease. For about 67% of patients, the planned treatment was
oxaliplatin and capecitabine, with the remaining 33% planned to receive oxaliplatin and 5FU. Baseline
characteristics were comparable for the 3-month and 6-month treatment groups for the overall patient
population (Table 1) and for the other analysis sets considering toxicity and HRQoL (see Appendix 1).
Exposure to study medication
The duration of adjuvant chemotherapy, based on the number of treatment cycles delivered, is presented
in Table 2; for the purpose of this analysis, one cycle of oxaliplatin and 5FU equated to 2 weeks of
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Randomised to study before starting
adjuvant chemotherapy
(n = 5929) 
Registered to study before starting
adjuvant chemotherapy (n = 215)
to be randomised at 3 months
Follow-up on 3035 patients
Allocated to 3 months’ treatment
(n = 3044)
Allocated to 6 months’ treatment
(n = 3044)
Follow-up on 3030 patients
Allocation
Efficacy analysis
Disease-free and
overall survival 
Randomised
(n = 6088) 
Enrolment
Treatment
• Patients with consent to use data , n = 3035
• Started study treatment, n = 3009
• Did not start study treatment, n = 26
   • Adverse event, n = 1
   • Protocol violation/ineligibility, n = 9
   • Clinical decision, n = 6
   • Patient decision, n = 4
   • Other, n = 9 (patient can have multiple
      reasons) – missing for 1 patient
• Patients with consent to use data, n = 3030
• Started study treatment, n = 3013
• Did not start study treatment, n = 17
   • Adverse event, n = 3
   • Protocol violation/ineligibility, n = 5
   • Clinical decision, n = 5
   • Patient decision, n = 4
   • Other, n = 2 (patient can have multiple
      reasons) – missing for 3 patients
CTC-graded AEs
(n = 434)
CTC-graded AEs
(n = 434)
Toxicity and QoL
analysis
Toxicity, QoL and
neurotoxicity in
subset of patients
Registered patients not randomised
at 3 months
(n = 56)
• Patients withdrew consent for use of on
   study data, n = 14
• Patients ineligible, n = 11
   • Wrong stage, n = 4
   • Excess delay from surgery to chemotherapy, n = 6
   • Not R0 resection, n = 1 (included in ITT analysis)
• Patient stopped treatment before
   3 months, n = 22
• Patient not fit to receive more than
   3 months of treatment, n = 6
• Patient withdrew consent, n = 1
• Other reason, n = 27
• Patients withdrew consent for use of on
   study data, n = 9
• Patients ineligible, n = 16
   • Wrong stage, n = 6
   • Excess delay from surgery to chemotherapy, n = 9
   • Not R0 resection, n = 1 (included in ITT analysis)
EORTC QLQ-C30/CR229
(n = 916)
EQ-5D
(n = 916)
FACT/GOG-Ntx4
(n = 1445)
EORTC QLQ-C30/CR229
(n = 913)
EQ-5D
(n = 912)
FACT/GOG-Ntx4
(n = 1426)
FIGURE 1 The CONSORT flow diagram of patient progression through the SCOT trial. Reproduced from
Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
(https://creativecommons.org/licenses/by/4.0/).
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TABLE 1 Baseline patient characteristics as recorded at randomisation, by treatment group
Characteristic
Randomised treatment group
3 months of treatment (N= 3044) 6 months of treatment (N= 3044)
Gender, n (%)
Female 1201 (39.5) 1200 (39.4)
Male 1843 (60.5) 1844 (60.6)
Total 3044 (100.0) 3044 (100.0)
Age (years)
Median 65 65
IQR 58–70 58–70
Range 23–84 20–85
Total 3044 3044
Performance status at randomisation, n (%)
0 2190 (71.9) 2144 (70.4)
1 854 (28.1) 900 (29.6)
Total 3044 (100.0) 3044 (100.0)
Disease site, n (%)
Colon 2492 (81.9) 2495 (82.0)
Rectum 552 (18.1) 549 (18.0)
Total 3044 (100.0) 3044 (100.0)
T stage, n (%)
0 1 (0.0) 3 (0.1)
1 92 (3.0) 95 (3.1)
2 284 (9.3) 283 (9.3)
3 1749 (57.5) 1748 (57.4)
4 917 (30.1) 915 (30.1)
X 1(0.0) 0 (0.0)
Total 3044 (100.0) 3044 (100.0)
N stage, n (%)
0 559 (18.4) 557 (18.3)
1 1731 (56.9) 1732 (56.9)
2 754 (24.8) 755 (24.8)
Total 3044 (100.0) 3044 (100.0)
Planned treatment, n (%)
FOLFOX 993 (32.6) 988 (32.5)
CAPOX 2051 (67.4) 2056 (67.5)
Total 3044 (100.0) 3044 (100.0)
If CAPOX planned, starting dose of capecitabine, n (%)
750mg/m2 348 (19.5) 349 (19.4)
800 mg/m2 72 (4.0) 78 (4.3)
1000mg/m2 1369 (76.5) 1370 (76.2)
Total 1789 (100.0) 1797 (100.0)
continued
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TABLE 1 Baseline patient characteristics as recorded at randomisation, by treatment group (continued )
Characteristic
Randomised treatment group
3 months of treatment (N= 3044) 6 months of treatment (N= 3044)
High-risk stage II, n (%)
No 2493 (81.9) 2499 (82.1)
Yes 551 (18.1) 545 (17.9)
Total 3044 (100.0) 3044 (100.0)
Randomisation time point, n (%)
Baseline 2964 (97.4) 2965 (97.4)
3 months 80 (2.6) 79 (2.6)
Total 3044 (100.0) 3044 (100.0)
CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU.
Adapted from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0
license (https://creativecommons.org/licenses/by/4.0/).
TABLE 2 Treatment duration by treatment group
Treatment
Duration of treatment (based on
the number of cycles) (weeks)
3-month treatment
(N= 3044), n (%)
6-month treatment
(N= 3044), n (%)
FOLFOX < 12 116 (11.8) 107 (10.9)
12 845 (86.2) 55 (5.6)
> 12, ≤ 16 18 (1.8) 64 (6.5)
> 16, ≤ 20 0 (0.0) 88 (8.9)
> 20, ≤ 24 1 (0.1) 74 (7.5)
24 0 (0.0) 586 (59.5)
> 24 0 (0.0) 11 (1.1)
Total 980 (100.0) 985 (100.0)
CAPOX < 12 310 (15.2) 310 (15.3)
12 1675 (81.9) 154 (7.6)
> 12, ≤ 16 59 (2.9) 75 (3.7)
> 16, ≤ 20 0 (0.0) 124 (6.1)
> 20, ≤ 24 0 (0.0) 141 (7.0)
24 0 (0.0) 1187 (58.5)
> 24 0 (0.0) 37 (1.8)
Total 2044 (100.0) 2028 (100.0)
All patients < 12 426 (14.1) 417 (13.8)
12 2520 (83.3) 209 (6.9)
> 12, ≤ 16 77 (2.5) 139 (4.6)
> 16, ≤ 20 0 (0.0) 212 (7.0)
> 20, ≤ 24 1 (0.0) 215 (7.1)
24 0 (0.0) 1773 (58.8)
> 24 0 (0.0) 48 (1.6)
Total 3024a (100.0) 3013b (100.0)
CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU.
a Missing for 20 patients: 9 withdrew consent for use of information, 11 had data missing.
b Missing for 31 patients: 14 withdrew consent for use of information, 17 had data missing.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
treatment and one cycle of oxaliplatin and capecitabine equated to 3 weeks of treatment. Overall, 83.3%
of patients randomised to the 3-month treatment group received 3 months of treatment: the frequency
was slightly higher for those receiving oxaliplatin and 5FU (86.2% of patients vs. 81.9% of those receiving
oxaliplatin and capecitabine). Overall, 58.8% of those randomised to the 6-month treatment group
received 6 months of treatment, with the proportion being similar for those receiving oxaliplatin and 5FU
(59.5%) and for those receiving oxaliplatin and capecitabine (58.5%); 6.9% of patients randomised to
6 months of treatment stopped treatment at 3 months. A total of 13.8% of patients stopped treatment
before 3 months, with the proportion being similar for those randomised to receive 3 months of treatment
(14.1%) and for those randomised to receive 6 months of treatment (13.8%).
The overall median treatment duration based on actual start and end dates was 11.3 weeks (IQR
10.1–12.6 weeks) for the 3-month treatment group and 23.1 weeks (IQR 17.0–25.3 weeks) for the
6-month treatment group. A higher proportion of patients receiving oxaliplatin and 5FU had at least one
delayed cycle in both the 3-month (65.0% vs. 45.2% with oxaliplatin and capecitabine) and the 6-month
(83.0% vs. 66.3%) treatment groups.
The median percentage of the full fluoropyrimidine dose delivered was 95.3% (IQR 83.1–99.8%) in the
3-month and 83.2% (IQR 56.7–95.7%) in the 6-month treatment groups. The median percentage of the
full oxaliplatin dose delivered was 96.6% (IQR 82.3% to 99.7%) in the 3-month and 70.2% (IQR 44.3%
to 87.1%) in the 6-month treatment groups. These values were similar irrespective of the fluoropyrimidine
backbone (Figure 2).
A total of 788 patients (26.2%) underwent 5FU or capecitabine dose reduction in the 3-month treatment
group compared with 1286 patients (42.7%) in the 6-month treatment group; 906 patients (30.1%)
underwent oxaliplatin dose reduction in the 3-month treatment group compared with 1869 patients
(62.0%) in the 6-month treatment group.
As patients receiving oxaliplatin and 5FU require insertion of a line, this could potentially delay the start of
their treatment. However, the difference in mean time from surgery to the start of adjuvant chemotherapy
was negligible when comparing patients treated with oxaliplatin and 5FU [mean 58 days, standard
deviation (SD) 16 days)] and those treated with oxaliplatin and capecitabine (mean 56 days, SD 14 days).
Comparison of efficacy for 3-month versus 6-month
adjuvant chemotherapy
Disease-free survival
By the time of analysis there had been 1482 DFS events (740 in the 3-month treatment group and 742 in
the 6-month treatment group). In the 3-month treatment group, 658 patients (21.7%) experienced disease
recurrence, 71 patients (2.1%) died without disease recurrence or a new primary colorectal lesion, and
11 patients (0.4%) had a new primary colorectal cancer lesion; in the 6-month treatment group, 654 patients
(21.6%) experienced disease recurrence, 76 patients (2.6%) died without disease recurrence or new primary
colorectal lesion, and 12 patients (0.4%) had a new primary colorectal cancer lesion. The 3-year DFS rate in
the 3-month treatment group was 76.7% [standard error (SE) 0.8%] and in the 6-month treatment group
was 77.1% (SE 0.8%); this equated to a HR of 1.006 [95% CI 0.909 to 1.114; p-value for non-inferiority
(pNI) = 0.012] and therefore met the criteria confirming non-inferiority for 3-month compared with 6-month
adjuvant chemotherapy (Figure 3).
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FIGURE 2 Treatment delivery by treatment group and adjuvant regimen. (a) Treatment duration; (b) percentage
of intended oxaliplatin dose; and (c) percentage of intended 5FU/capecitabine dose. Boxes show median and
IQR; whiskers show range; dots represent outliers. FOLFOX, oxaliplatin and 5FU. Adapted from Iveson et al.16
© The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
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Sensitivity analysis considered the difference between treatment groups based on the actual duration of
treatment (Figure 4). For eligible patient who received 3 months (2513 patients; see Table 2) or 6 months
(1771 patients; see Table 2) of adjuvant chemotherapy, the observed HR was 1.158 (95% CI 1.018, 1.317;
p = 0.641) with non-inferiority not confirmed in any of these smaller, non-ITT populations.
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Heterogeneity of the 3-month versus 6-month effect was assessed for the stratification factors used for
randomisation and for the randomisation time-point. The resulting HRs, 95% CIs and p-values testing the
heterogeneity of the treatment-duration effect for these subgroups are presented in Figure 5. The adjuvant
treatment regimen selected at randomisation was associated with a trend towards heterogeneity in
effect (p = 0.069).
Further (post hoc) analysis of DFS for patients receiving 3-month or 6-month duration adjuvant chemotherapy
was conducted separately for patients who received oxaliplatin and 5FU and for patients who received
oxaliplatin and capecitabine (Figure 6). For patients receiving oxaliplatin and capecitabine, the 3-year DFS rate
for the 3-month treatment group was 76.9% (SE 1.0%) and for the 6-month treatment group was 76.1%
(SE 1.0%), resulting in a HR of 0.944 (95% CI 0.835 to 1.067; pNI = 0.002), which met the criteria for
non-inferiority. However, for patients receiving oxaliplatin and 5FU, the 3-year DFS for the 3-month treatment
group was 76.3% (SE 1.4%) and for the 6-month treatment group was 79.2% (SE 1.3%), resulting in a HR
of 1.158 (95% CI 0.964 to 1.391; pNI = 0.591), which did not meet the non-inferiority criteria.
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FIGURE 4 Plot of 3-month/6-month HR by actual treatment duration (analysis according to duration restricted to
eligible patients who started treatment) with associated non-inferiority p-values. Reproduced from Iveson et al.16
© The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
(https://creativecommons.org/licenses/by/4.0/).
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FIGURE 5 Disease-free survival and heterogeneity in subgroups by minimisation variables. Categories are listed as recorded at randomisation; 10 patients in the 3-month
treatment group and 15 patients in the 6-month treatment group could not be allocated to high-risk stage II or stage III based on T/N data recorded at randomisation.
CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU. Adapted from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under
the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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Previous clinical trials in patients with colorectal cancer have shown a marked difference in the risk of
relapse between patients with T1–3, N1 disease and those with T4 or N2 disease.29 Post hoc analyses were
therefore conducted to assess whether or not disease stage affected DFS rate for patients with differing
adjuvant treatment durations. Kaplan–Meier curves (Figure 7) showed that 3-year DFS for patients with
T1–3, N1 primary disease in the 3-month treatment group reached 85.3% (SE 1.0%) and for the 6-month
treatment group reached 84.0% (SE 1.0%), giving a HR of 0.907 (95% CI 0.749 to 1.097; pNI = 0.011).
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FIGURE 6 Disease-free survival by treatment group and adjuvant chemotherapy regimen. (a) CAPOX; and
(b) FOLFOX. CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU. Adapted with minor corrections
from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0
license (https://creativecommons.org/licenses/by/4.0/).
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For patients with T1–3, N1 disease non-inferiority was, therefore, demonstrated when comparing 3-month
with 6-month chemotherapy. For stage III colorectal cancer patients with T4 and/or N2 pathology, 3-year
DFS for the 3-month treatment group was 63.0% (SE 1.5%) and for the 6-month treatment group was
64.8% (SE 1.4%), giving a HR of 1.069 (95% CI 0.935 to 1.222; pNI = 0.19), which did not meet the
non-inferiority criteria.
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FIGURE 7 Disease-free survival by treatment group and disease stage. (a) T1–3 or N1; and (b) T4 or N2. Adapted
with minor corrections from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article
under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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Analysis of these prognostic groups according to the chemotherapy regimen they received (Figure 8)
showed that Kaplan–Meier DFS curves suggest that 3 months of treatment with oxaliplatin and oxaliplatin
(CAPOX) may be adequate both for T1–3, N1 and for T4 and/or N2 patients (most reliably for T1–3, N1),
but this is not as clear for oxaliplatin and 5FU (FOLFOX), particularly for T4 and/or N2.
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FIGURE 8 Disease-free survival by treatment group, disease stage, and adjuvant chemotherapy regimen.
(a) Low-risk stage III (T1–3, N1)/FOLFOX; (b) low-risk stage III (T1–3, N1)/CAPOX; (c) high-risk stage III (T4 or N2)/
FOLFOX; and (d) high-risk stage III (T4 or N2)/CAPOX. CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin
and 5FU. Adapted from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article
under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/). (continued )
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Note that although curves in some of the subgroups in Figures 7 and 8 cross, there is no suggestion in any
case that the proportional-hazards assumption is violated (minimum p-value testing for non-proportionality,
p = 0.226).
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FIGURE 8 Disease-free survival by treatment group, disease stage, and adjuvant chemotherapy regimen.
(a) Low-risk stage III (T1–3, N1)/FOLFOX; (b) low-risk stage III (T1–3, N1)/CAPOX; (c) high-risk stage III (T4 or N2)/
FOLFOX; and (d) high-risk stage III (T4 or N2)/CAPOX. CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin
and 5FU. Adapted from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article
under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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Overall survival
By the time of analysis, 787 participants in the 3-month treatment group had died [393 (12.9% of 3035
in the efficacy analysis) and 394 participants in the 6-month treatment group had died (13.0% of the
3030 in the efficacy analysis). The 3-year overall survival rate for the 3-month treatment group was 90.0%
(SE 0.6%) and for the 6-month treatment group was 89.6% (SE 0.6%), equating to a HR of 0.994 (95% CI
0.964 to 1.143; pNI = 0.035; see Figure 3b). Sixteen deaths in each treatment group were considered related
to study medication.
Safety
The occurrence of AEs was analysed for a total of 868 patients, comprising 434 patients in each treatment
group. Table 3 shows the maximum NCI CTCAE grade recorded per patient for AEs with an incidence of
≥ 10% in either treatment group. Most of these events (alopecia, anaemia, anorexia, diarrhoea, fatigue,
hand–foot syndrome, mucositis, sensory neuropathy, neutropenia, pain, rash, altered taste, thrombocytopenia
and watery eye) showed a statistically significant increase in grade for the 6-month treatment group compared
with the 3-month treatment group.
The overall frequency of grade ≥ 3 toxicity was 59.4% for 6-month duration adjuvant chemotherapy and
35.7% for 3-month adjuvant chemotherapy (p < 0.001). Sensory neuropathy, diarrhoea, neutropenia,
fatigue, pain, nausea and hand–foot syndrome were the most common grade ≥ 3 AEs reported. The
difference in frequency between treatment groups was statistically significant for diarrhoea (p = 0.033),
neutropenia (p = 0.023), pain (p = 0.014), hand–foot syndrome (p = 0.031) and sensory neuropathy
(p < 0.001). The AE for which there was the most marked increase in the proportion of patients with
grade ≥ 3 with 6-month adjuvant chemotherapy was sensory neuropathy (16.4% vs. 4.3% with
3-month treatment).
The proportion of those with febrile neutropenia was 1.6% of patients for the 3-month treatment group
and 1.2% for the 6-month treatment group. Figure 9 shows that diarrhoea and hand–foot syndrome were
more common in patients receiving oxaliplatin and capecitabine and that neutropenia was more common
in those receiving oxaliplatin and 5FU.
A total of 244 patients in the 3-month treatment group and 576 patients in the 6-month treatment group
cited AEs as the reason for stopping treatment early. The most frequently cited AEs leading to treatment
discontinuation were diarrhoea (n = 90 patients) for the 3-month treatment group, and diarrhoea
(n = 150 patients) and peripheral neuropathy (n = 156 patients) for the 6-month treatment group.
Serious adverse reactions were reported for 421 patients in the 3-month treatment group and for
511 patients in the 6-month treatment group. Gastrointestinal SAEs were most common and occurred
in similar proportions of patients in both groups. Thirty-two patients died owing to events attributed to
treatment toxicity, with the events distributed equally between the groups (16 patients died in each
group); 27 of these deaths occurred during the first 3 months of treatment. A total of 21 patients of
the 4108 who received oxaliplatin and capecitabine (0.51%) and 11 patients of the 1980 who received
oxaliplatin and 5FU (0.56%) were reported to have died from toxicity.
Peripheral neuropathy was also assessed using a patient-reported outcome (PRO) FACT/GOG-Ntx4
questionnaire. Data were available for 2871 patients who were assessed for up to 7 years. The mean
FACT/GOG-Ntx4 questionnaire neuropathy scores for patients receiving 3-month and 6-month adjuvant
chemotherapy are shown in Figure 10. The neurotoxicity standardised-adjusted AUC differed markedly
between the groups (p < 0.001), with a higher rate of neuropathy for the 6-month treatment group being
clearly apparent from 4 months and persisting to ≥ 5 years (p < 0.001). Peak neuropathy occurred at
6 months for the 3-month treatment group and at 9 months for the 6-month treatment group.
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TABLE 3 Maximum NCI CTCAE grade of toxicity recorded during treatment by randomised treatment group (for toxicities with an incidence of ≥ 10%)
Adverse event
Randomised treatment group, n (%)
p-value
(comparison
of ordered
categories)
p-value
(comparison of
percentage of
grade 3/4/5
adverse events)
Odds ratio for
incidence of grade
3/4/5 toxicities
(6 months/3 months)
from logistic
regression (CI)
3 months of treatment (N= 434) 6 months of treatment (N= 434)
0 1–2 3 4 Missing 0 1–2 3 4 5 Missing
Alopecia 345 (83.3) 69 (16.7) 0 (0.0) 0 (0.0) 20 (–) 309 (76.1) 97 (23.9) 0 (0.0) 0 (0.0) 0 (0.0) 28 (–) 0.0094 – Not estimable
Anaemia 270 (64.7) 143 (34.3) 2 (0.5) 2 (0.5) 17 (–) 212 (52.2) 190 (46.8) 3 (0.7) 1 (0.2) 0 (0.0) 28 (–) 0.00013 1.00 1.027 (0.255–0.4.136)
Anorexia 312 (75.9) 92 (22.4) 7 (1.7) 0 (0.0) 23 (–) 262 (64.7) 140 (34.6) 3 (0.7) 0 (0.0) 0 (0.0) 29 (–) 0.00043 0.34 0.431 (0.111–1.677)
Constipation 289 (69.8) 122 (29.5) 2 (0.5) 1 (0.2) 20 (–) 268 (66.0) 135 (33.3) 3 (0.7) 0 (0.0) 0 (0.0) 28 (–) 0.28 1.00 1.010 (0.205–5.083)
Diarrhoea 128 (30.7) 243 (58.3) 44 (10.6) 2 (0.5) 17 (–) 99 (24.4) 241 (59.4) 63 (15.5) 2 (0.5) 1 (0.2) 28 (–) 0.0079 0.033 1.566 (1.045–2.345)
Fatigue 58 (14.0) 320 (77.1) 35 (8.4) 2 (0.5) 19 (–) 41 (10.1) 333 (82.0) 32 (7.9) 0 (0.0) 0 (0.0) 28 (–) 0.022 0.62 0.874 (0.533–1.433)
Hand–foot
syndrome
277 (66.9) 129 (31.2) 8 (1.9) 0 (0.0) 20 (–) 218 (53.7) 169 (41.6) 18 (4.4) 1 (0.2) 0 (0.0) 28 (–) <0.0001 0.031 2.492 (1.078–5.758)
Mucositis
(clinical exam)
355 (86.0) 56 (13.6) 2 (0.5) 0 (0.0) 21 (–) 320 (79.0) 83 (20.5) 1 (0.2) 0 (0.0) 1 (0.2) 29 (–) 0.013 1.00 1.020 (0.143–7.275)
Mucositis
(functional/
symptomatic)
283 (68.4) 127 (30.7) 4 (1.0) 0 (0.0) 20 (–) 242 (59.6) 159 (39.2) 4 (1.0) 0 (0.0) 1 (0.2) 28 (–) 0.0066 0.75 1.278 (0.341–4.794)
Nausea 147 (35.3) 249 (59.9) 20 (4.8) 0 (0.0) 18 (–) 120 (29.6) 277 (68.2) 9 (2.2) 0 (0.0) 0 (0.0) 28 (–) 0.26 0.057 0.449 (0.202–0.998)
Neuropathy:
sensory
37 (8.8) 365 (86.9) 18 (4.3) 0 (0.0) 14 (–) 28 (6.8) 314 (76.8) 65 (15.9) 2 (0.5) 0 (0.0) 25 (–) <0.0001 <0.0001 4.375 (2.550–7.508)
Neutropenia 287 (69.0) 90 (21.6) 23 (5.5) 16 (3.8) 18 (–) 221 (54.4) 127 (31.3) 43 (10.6) 14 (3.4) 1 (0.2) 28 (–) <0.0001 0.031 1.611 (1.046–2.480)
Pain: other
(specify)
311 (74.0) 99 (23.6) 10 (2.4) 0 (0.0) 14 (–) 278 (68.0) 107 (26.2) 24 (5.9) 0 (0.0) 0 (0.0) 25 (–) 0.026 0.014 2.556 (1.206–5.415)
Rash 359 (86.9) 52 (12.6) 2 (0.5) 0 (0.0) 21 (–) 320 (79.0) 84 (20.7) 1 (0.2) 0 (0.0) 0 (0.0) 29 (–) 0.00061 1.00 0.509 (0.046–5.632)
Taste alteration 231 (56.1) 180 (43.7) 1 (0.2) 0 (0.0) 22 (–) 179 (44.4) 222 (55.1) 2 (0.5) 0 (0.0) 0 (0.0) 31 (–) 0.0021 0.57 2.050 (0.185–22.696)
Thrombocytopenia 290 (69.7) 117 (28.1) 5 (1.2) 4 (1.0) 18 (–) 253 (62.3) 145 (35.7) 5 (1.2) 2 (0.5) 1 (0.2) 28 (–) 0.020 1.00 0.909 (0.347–2.380)
Vomiting 304 (73.1) 98 (23.6) 14 (3.4) 0 (0.0) 18 (–) 270 (66.5) 126 (31.0) 10 (2.5) 0 (0.0) 0 (0.0) 28 (–) 0.056 0.54 0.725 (0.318–1.652)
Watery eye 339 (82.7) 71 (17.3) 0 (0.0) 0 (0.0) 24 (–) 310 (76.7) 92 (22.8) 2 (0.5) 0 (0.0) 0 (0.0) 30 (–) 0.028 0.25 Not estimable
Adapted from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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FIGURE 9 Frequency of patients with selected grade ≥ 3 toxicities, by treatment group and treatment regimen.
(a) CAPOX 3 months; (b) CAPOX 6 months; (c) FOLFOX 3 months; and (d) FOLFOX 3 months. CAPOX, oxaliplatin
and capecitabine; FOLFOX, oxaliplatin and 5FU.
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FIGURE 10 Peripheral neuropathy score, by treatment group. Data beyond year 6 were omitted because of small numbers. Error bars show 95% CIs. a, Low completion rate
at these time points reflect the fact that neurotoxicity data were initially collected only up to 12 months; b, low return rate because patients were assessed at the start of
the last cycle rather than at 6 months. Adapted from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
(https://creativecommons.org/licenses/by/4.0/). (continued )
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Number of patients completing questionnaire
Year 6Year 5Year 4Year 3aYear 2aYear 1 Month 18aMonth 9Month 6Month 5Month 4Month 3Month 2Month 1
(b)
Baseline
54193286198169721 172733606638639527782817859
8431359088712021366 131213861400141314161421142614331445
646249221453 135343454537555759
54170257199174721 182665298624679701782796865
8531761088711951346 130813661375138213841389139514061426
645442221554 134920b454951565761
Completed (n)
3 months
of
treatment
6 months
of
treatment
Expected (n)
Expected (%)
Completed (n)
Expected (n)
Expected (%)
FIGURE 10 Peripheral neuropathy score, by treatment group. Data beyond year 6 were omitted because of small numbers. Error bars show 95% CIs. a, Low completion rate
at these time points reflect the fact that neurotoxicity data were initially collected only up to 12 months; b, low return rate because patients were assessed at the start of
the last cycle rather than at 6 months. Adapted from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
(https://creativecommons.org/licenses/by/4.0/).
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Health-related quality of life
A total of 1829 patients provided data on the EORTC questionnaires. Global health status and all
functional and symptom scales of the EORTC QLQ-C30 showed statistically significant differences in terms
of standardised-adjusted AUC, indicating better functioning and fewer side effects in patients receiving
3-month adjuvant chemotherapy. Scores for the two groups mirrored each other over the first 3 months of
treatment but subsequently improved from months 4 to 6 for patients in the 3-month treatment group,
indicative of functional improvement and decreased side effects in those who stopped treatment at
3 months (Figure 11). For the EORTC QLQ-CR29, statistically significant differences were apparent for
body image (p = 0.037), dry mouth (p < 0.0001), hair loss (p = 0.035) and taste (p < 0.0001) scales.
The magnitudes of the mean differences in functional and global health status scales between treatment
groups were indicative of ‘moderate’ differences for global health status, role functioning, and social
function and ‘a little’ difference for physical, emotional and cognitive functions.22
A total of 1828 patients provided data on the EQ-5D. Statistically significant differences in standardised-
adjusted AUC were seen for both the EQ-5D self-rated visual analogue scale (p = 0.00081) and the EQ-5D-3L
health index (p = 0.00081). Differences between the two treatment groups were apparent from months
4 to 6 (Figure 12), consistent with the time when those in the 6-month treatment group were still receiving
treatment but those in the 3-month treatment group had finished. From 9 months to the 7-year follow-up,
there were no clinically relevant differences23 between the treatment groups.
Given the notable number of missing data for HRQoL assessments (FACT/GOG-Ntx4, EORTC and EQ-5D),
the reasons for missing questionnaires were analysed and are presented in Appendix 2. Missing
questionnaire data were generally related to various errors. Patients who did complete questionnaires were
shown to be representative of the overall study population, with no indication that missing data were
associated with any particular baseline characteristic. Sensitivity analyses comparing the primary results
with those based on just observed data or using data imputed only for patients who completed baseline
questionnaires showed similar results.
Exploratory analysis considered differences in HRQoL scales when comparing patients with ‘quite a bit’/
‘very much’ numbness or tingling or discomfort in hands or feet on the FACT/GOG-Ntx4 toxicity
questionnaire with those who rated these symptoms as ‘somewhat’/‘a little bit’/‘not at all’. The proportion
of patients recording neuropathy symptoms as being present ‘quite a bit’ or ‘very much’ was higher for
patients in the 6-month treatment group at 1 year (34% vs. 14% of patients in the 3-month treatment
group), 3 years (32% vs. 17%) and 5 years (29% vs. 16%). This analysis consistently demonstrated
statistically significantly poorer HRQoL across the different scales for patients who had ‘quite a bit’ or
‘very much’ recorded for neuropathy symptoms, at all time points (p < 0.001; Figure 13).
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FIGURE 11 The EORTC global health status, by treatment group. a, Low return rate as patients were assessed at the start of the last cycle rather than at 6 months.
Reproduced from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license (https://creativecommons.org/
licenses/by/4.0/). (continued )
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Number of patients completing questionnaire
Year 1Month 9Month 6Month 5Month 4Month 3Month 2Month 1
(b)
Baseline
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863873878885886889895902913
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3 months
of
treatment
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of
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Completed (n)
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FIGURE 11 The EORTC global health status, by treatment group. a, Low return rate as patients were assessed at the start of the last cycle rather than at 6 months.
Reproduced from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license (https://creativecommons.org/
licenses/by/4.0/).
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FIGURE 12 The EQ-5D self-rated visual analogue scale, by treatment group. Data beyond year 6 were omitted because of small numbers. a, Low return rate as patients were
assessed at the start of the last cycle rather than at 6 months. VAS, visual analogue scale. Reproduced from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an
Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/). (continued )
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Number of patients completing questionnaire
Year 6Year 5Year 4Year 3Year 2Year 1 Month 18Month 9Month 6Month 5Month 4Month 3Month 2Month 1
(b)
Baseline
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FIGURE 12 The EQ-5D self-rated visual analogue scale, by treatment group. Data beyond year 6 were omitted because of small numbers. a, Low return rate as patients were
assessed at the start of the last cycle rather than at 6 months. VAS, visual analogue scale. Reproduced from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an
Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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FIGURE 13 Differences in HRQoL assessments based on the degree of numbness/tingling/discomfort in hands or
feet. (a) EQ-5D visual analogue scale 1 year; (b) EQ-5D-3L health index 1 year; (c) EORTC global quality of life
1 year; (d) EQ-5D visual analogue scale 3 years; (e) EQ-5D-3L health index 3 years; (f) EQ-5D visual analogue scale
5 years; and (g) EQ-5D-3L health index 5 years. No/yes on all the x-axes refers to whether or not the patient
experienced ‘quite a bit/very much numbness or tingling or discomfort in hands or feet’ on the FACT/GOG-Ntx4
toxicity score. Adapted from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article
under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/). (continued )
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FIGURE 13 Differences in HRQoL assessments based on the degree of numbness/tingling/discomfort in hands or
feet. (a) EQ-5D visual analogue scale 1 year; (b) EQ-5D-3L health index 1 year; (c) EORTC global quality of life
1 year; (d) EQ-5D visual analogue scale 3 years; (e) EQ-5D-3L health index 3 years; (f) EQ-5D visual analogue scale
5 years; and (g) EQ-5D-3L health index 5 years. No/yes on all the x-axes refers to whether or not the patient
experienced ‘quite a bit/very much numbness or tingling or discomfort in hands or feet’ on the FACT/GOG-Ntx4
toxicity score. Adapted from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article
under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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Chapter 4 Economic analyses
Methodology
The economic analysis was undertaken from the perspective of the UK NHS and Personal Social Services
for the 2016 base year, adhering to good practice guidelines.30,31 A within-trial analysis utilised the
individual patient-level data on resource use, HRQoL (EQ-5D-3L) and survival.
Outcome data
The effectiveness measure for the economic analysis was the discounted QALY gain per patient; QALYs
were calculated using quality-adjusted survival analysis.32 Overall survival data from the SCOT study were
partitioned into three health states: time on treatment (ToT), disease-free state post treatment and recurrence
(Figure 14). The model begins with patients who have undergone surgery and are now assumed to be
disease-free, who begin treatment with chemotherapy (ToT state). After completing treatment, patients move
into the disease-free state and remain here until they experience a recurrence or die. Patients who experience
a recurrence remain in the recurrence state until they die.
Kaplan–Meier survival estimates were used for computation of quality-adjusted survival time in each health
state over the 8-year within-trial period. A separate model estimated HRQoL for each health state.
The EQ-5D-3L data were collected for a subsample of 1832 patients (about 30% of the study sample) at
baseline and all follow-up times and combined with the UK EQ-5D-3L health-utility scores20 to calculate
utilities. Table 4 details the characteristics of patients by EQ-5D subsample in comparison with the whole
study sample. An interim analysis33 of the SCOT study EQ-5D and AE data showed that adequate data
were collected from the first 1832 patients in the SCOT study; therefore, discontinuation of the EQ-5D was
recommended for new study recruits beyond that point. To control for plausible differences between the
EQ-5D and total study populations, the HRQoL model included co-variables such as planned treatment,
high-risk disease, gender, age and ethnicity. The model predicts health utilities for the average
characteristics of the patients in each health state.
Time on treatment Disease-free
state
Recurrence
Dead
FIGURE 14 Partitioned survival model.
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A linear regression with SEs clustered at the individual level estimated the HRQoL, including the following
independent variables: health state, treatment group and individual characteristics. Time in the health
states – ToT, disease-free state and recurrence – was computed by integration of the Kaplan–Meier curves
and then adjusted by HRQoL using the method of integrated quality-survival product to compute QALYs.
This approach to quality-adjusted survival analysis avoids problems with informative censoring in survival
analysis based on individual QALYs as an end point.34
Cost data
The main cost categories were chemotherapy treatment and hospitalisation. Costs associated with patient
treatment were calculated by measuring and valuing resources used by trial participants during the
treatment and follow-up periods. Patient-level resource-use data were collected for adjuvant chemotherapy
dose/duration and hospitalisation during treatment and follow-up for the whole study sample. Costs were
valued in 2016 Great British pounds. The oxaliplatin, capecitabine and 5FU doses administered were
recorded, and the numbers of each were combined with their unit costs; the cost per mg of each drug
was obtained from the British National Formulary 73, where the lowest price per unit available was used.35
Hospitalisation costs incurred by patients receiving adjuvant chemotherapy and being treated for adverse
reactions were recorded. Hospitalisation resource use data included overnight stays in an intensive care
unit, a high-dependency unit and general medicine wards,36 and inpatient chemotherapy administration
as well as day cases and outpatient cases. Primary care costs (general practitioner visits) were less relevant
to this context and were therefore excluded. Direct and non-direct costs for each hospitalisation were
obtained from the Information Services Division of NHS Scotland.37 Direct costs were attributed to medical,
nursing, health professional, pharmacy, theatre, laboratory and other costs. For inpatient and day cases
occurring within the treatment period, the pharmacy cost was subtracted to avoid double-counting
TABLE 4 Patient characteristics by EQ-5D subsample
Characteristic Total (N= 6065) Non-EQ-5D (N= 4308) EQ-5D (N= 1757) p-value
Planned treatment (%)
Oxaliplatin and capecitabine 67.5 67.5 67.5
Oxaliplatin and 5FU 32.5 32.5 32.5 0.99
Gender (%) and age (mean)
Female 39.46 39.65 38.99
Male 60.54 60.35 61.01 0.633
Age 63.43 63.35 63.62 0.3094
Disease risk (%)
High 53.19 54.32 50.43
Low 46.81 45.68 49.57 0.006
Ethnicity (%)
White/Caucasian 94.02 82.61 77.95
African/Caribbean 1.37 1.09 0.97
South Asian 1.42 1.02 0.86
Chinese 0.4 0.25 0.19
Other 2.79 15.04 20.03 < 0.001
Note
Differences between groups were tested with a chi-squared test (planned treatment, gender, disease risk and ethnicity) or
t-test (age).
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chemotherapy medication. The cost of treating AEs was assumed to be included in hospitalisation costs for
patients attending hospital for night or day cases or during outpatient visits.
Given that the follow-up period differed among patients, the total cost per patient was estimated as the
Kaplan–Meier survival analysis;38 this allowed the average total cost to be estimated as the sum of the
average cost for each period multiplied by the probability of surviving at the beginning of the period.
Cost-effectiveness
The cost and QALY outcomes for each treatment group were estimated and combined with the upper
UK decision threshold for cost-effectiveness of £30,000 per QALY30 to report outcomes in terms of NMB
according to good reporting practice guidance.39 The incremental NMB is the difference between the NMB
of the two groups.
Analyses were performed using Stata 14.0 (StataCorp LP, College Station, TX, USA) to compare mean cost
and mean QALY differences between the treatment groups (3-month vs. 6-month treatment) and the
NMB was reported in line with recent reporting guidelines39 and the UK reference case.30 Discounting of
costs and QALY outcomes beyond 1 year was applied at a rate of 3.5%.30
Bootstrapping (1000 iterations)40 was used to account for uncertainty around the difference in costs and
QALYs and to assess how this uncertainty affects the cost-effectiveness outcome. Uncertainty was reported
through CIs and the computation of cost-effectiveness acceptability probabilities was estimated as a function
of the threshold for the monetary value of a QALY.41 Subgroup analyses were undertaken, in line with the
main trial analyses, to consider cost-effectiveness of the two treatment duration strategies according to
planned treatment regimen (oxaliplatin and 5FU or oxaliplatin and capecitabine), disease risk (high or low),
gender and age.
Results
Cost-effectiveness analyses were conducted on information provided by the 6065 patients who consented
to their data being used (see Figure 1).
Effectiveness
Kaplan–Meier estimates up to 8 years after randomisation were used to determine how overall survival
time would be split into the three health states – ToT, disease-free and recurrence – for the two treatment
groups, as shown in Table 5. As would be expected, ToT was significantly higher for patients in the
6-month treatment group, whereas disease-free was just outside the 5% statistical-significance level but
TABLE 5 Overall survival time (restricted mean survival) up to 8 years by health status and treatment group
Survival analysis
(restricted mean survival)
3-month treatment,
mean (n= 3035 patients)
6-month treatment,
mean (n= 3030 patients)
Incremental difference
Mean p-value
Time-on-treatmenta 0.21 0.39 –0.18 0.000
Disease-free 5.93 5.74 0.19 0.053
Recurrence 0.73 0.77 –0.041 0.605
Total (overall survival) 6.87 6.90 –0.032 10.695
a Estimation of time-on-treatment was based on 3018 and 3013 patients for the 3-month and 6-month treatment groups
respectively, owing to missing values.
Notes
Kaplan–Meier estimates were used for computation of expected time in each health state. Survival time (restricted mean
survival) was estimated to 8 years post randomisation.
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favoured the 3-month treatment group. No difference was seen between the groups for time in recurrence
or overall survival. Figure 15 shows the time of overall survival partitioned into ToT, disease-free state and
recurrence state for the two treatment groups, as generated using Kaplan–Meier estimates.
Kaplan–Meier estimates of how overall survival time would be split into the three health states – ToT,
disease-free and recurrence – for the two treatment groups, by subgroup, are shown in Table 6.
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0.25
0.50
0.75
1.00
ToT
DF state
Recurrence
(a)
0 1 2 3 4 5 6 7 8
Years from randomisation
0.00
0.25
0.50
0.75
1.00
ToT
DF state
Recurrence
(b)
FIGURE 15 Overall survival partitioned into ToT, disease-free state after treatment, and recurrence, Kaplan–Meier
estimates over 8 years, by treatment group at (a) 3 months and (b) 6 months. DF, disease free.
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Table 7 shows the results of the utility model for non-missing observations. The effect of recurrence and
ToT was captured by assigning a value of 1 to the EQ-5D responses occurring in those health states. ToT
and recurrence have a significant negative effect on utility, as would be expected; however, the 3-month
treatment group was estimated to have higher HRQoL (p < 0.05) even after controlling for recurrence and
ToT. These results are consistent with the higher incidence of AEs in the 6-month than in the 3-month
TABLE 6 Overall survival time by health state: subgroup analysis
Health state
3-month
treatment,
mean
6-month
treatment,
mean
Incremental
difference,
mean (p-value)
3-month
treatment,
mean
6-month
treatment,
mean
Incremental
difference,
mean (p-value)
By planned treatment
Oxaliplatin and 5FU (N = 1971) Oxaliplatin and capecitabine (N = 4094)
Patients (n) 984 987 2051 2043
Recurrence 0.78 0.67 0.11 (0.336) 0.71 0.82 –0.10 (0.336)
Disease-free 5.81 5.96 –0.14 (0.360) 5.98 5.63 0.35 (0.004)
ToT 0.22 0.42 0.20 (< 0.001) 0.20 0.37 –0.17 (< 0.001)
Total
(overall survival)
6.82 7.05 –0.22 (0.128) 6.90 6.83 0.071 (0.508)
By risk
High risk (N = 2839) Low risk (N = 3226)
Patients (n) 1424 1415 1611 1615
Recurrence 0.95 0.86 0.08 (0.434) 0.55 0.71 –0.16 (0.158)
Disease-free 5.14 5.10 0.04 (0.739) 6.62 6.30 0.32 (0.016)
ToT 0.21 0.40 –0.18 (< 0.001) 0.21 0.39 –0.18 (< 0.001)
Total
(overall survival)
6.31 6.36 –0.048 (0.736) 7.39 7.42 –0.023 (0.806)
By gender
Female (N = 2393) Male (N = 3672)
Patients (n) 1199 1194 1836 1836
Recurrence 0.60 0.67 –0.07 (0.576) 0.82 0.84 –0.02 (0.817)
Disease-free 6.10 5.73 0.37 (0.006) 5.80 5.74 0.053 (0.690)
ToT 0.21 0.38 –0.16 (< 0.001) 0.21 0.40 –0.19 (< 0.001)
Total
(overall survival)
6.92 6.78 0.14 (0.279) 6.82 6.98 –0.16 (0.195)
By age
≥ 65 years (N = 3065) < 65 years (N = 3000)
Patients (n) 1525 1540 1510 1490
Recurrence 0.80 0.65 0.15 (0.287) 0.69 0.89 –0.20 (0.042)
Disease-free 5.72 5.69 0.03 (0.838) 6.10 5.78 0.31 (0.013)
ToT 0.21 0.38 –0.16 (< 0.001) 0.21 0.41 –0.20 (< 0.001)
Total
(overall survival)
6.73 6.72 0.02 (0.900) 7.01 7.09 –0.077 (0.518)
Notes
Kaplan–Meier estimates were used for computation of expected time in each health state. Survival time was estimated up
to 8 years post randomisation.
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treatment group. Patient characteristics were included in the model to adjust health utilities to the average
values for the whole SCOT study sample, with and without the EQ-5D data. A statistically significant
positive effect on HRQoL was associated with the variables male and age, with a negative effect seen for
African/Caribbean and South Asian patients compared with white/Caucasian patients. Planned treatment
and disease risk did not have a significant effect.
The results of the model follow the pattern of the evolution of EQ-5D scores over time as shown in
Figure 16. After baseline, HRQoL decreased for both groups to 3 months; at this point, health utilities for
those in the 3-month treatment group increased as they completed treatment, whereas lower HRQoL
persisted for patients receiving 6 months of adjuvant chemotherapy. Changes in HRQoL were primarily
related to ToT, although Figure 16 illustrates that some difference in HRQoL was evident between the two
groups beyond 6 months (completion of adjuvant chemotherapy).
TABLE 7 Health utilities regression
Variable Coefficient Standard error
Number of patientsa (n) 1757
Number of observations (n) 16,091
Health states (reference: disease-free)
ToT –0.0394d 0.00408
Recurrence –0.0578d 0.0139
Treatment group: 6 months –0.0154b 0.00730
Other characteristics
Oxaliplatin and capecitabine 0.00402 0.00783
High risk –0.00911 0.00724
Male 0.0159b 0.00733
Age 0.00162d 0.000429
Ethnicity (reference: white/Caucasian)
African/Caribbean –0.0810b 0.0385
South Asian –0.145c 0.0536
Chinese –0.0447 0.0772
Other 0.0178 0.0217
Constant 0.866d 0.00944
a The total number of EQ-5D questionnaires reported by the patients included in the estimation.
b p < 0.05.
c p < 0.01.
d p < 0.001.
Notes
The constant in the model refers to a 65-year-old white female patient with low-risk, stage III disease, in the disease-free
health state, who was treated with oxaliplatin and 5FU in the 3-month treatment group. Standard error clustered at the
patient level.
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Costs
The unit costs for treatment and hospitalisation are detailed in Table 8, and Table 9 provides a detailed
unit cost breakdown for each of the hospitalisation cost categories. Tables 10 and 11 detail resource use
for chemotherapy and hospitalisations, respectively, for each group of the intervention and by planned
treatment regimen.
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FIGURE 16 Evolution of EQ-5D utilities over time, by treatment group. Presented as means and 95% CIs.
TABLE 8 Unit costs used for cost-effectiveness analyses
Adjuvant chemotherapy
drug Description Cost (£) Unit cost (£/mg)
Oxaliplatin 200 mg/40 ml concentrate of oxaliplatin for
solution for infusion vials
595.65 2.98
Capecitabine 500-mg tablets of capecitabine, 120 tablets 146.00 2.43 × 10–3
5FU (bolus) 500 mg/20 ml solution of 5FU for injection
vials, 10 vials
64.00 1.28 × 10–2
5FU (infusion) 2.5 g/100 ml solution of 5FU for infusion vials 32.00 1.28 × 10–2
Hospitalisation type Description Unit cost (£/night or case)
Intensive care unit Night in intensive care unit 2190.35
High-dependency unit Night in intensive care unit 937.87
General medicine Night in general medicine unit 476.73
Inpatient (clinical oncology) Night in clinical oncology unit, as inpatient 896.88
Day case (clinical oncology) Day case at clinical oncology 813.22
Outpatient (clinical oncology) Outpatient attendance for clinical oncology 251.77
Notes
The lowest priced medication for each drug at the appropriate dosage was used, as described in the British National
Formulary 73.35 Hospitalisation unit costs are based on information reported by Information Services Division Scotland 2017
(reports: R040 – nights, R042 – day cases, R044 – outpatient).37
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TABLE 9 Hospitalisation unit costs
Hospitalisations
Cost per night or case (£)
Total cost (£)Medical Nursing Allied health professional Pharmacy Theatre Laboratory Other Non-direct costs
Intensive care unita 284.24 1029.79 36.63 263.48 9.83 76.44 22.35 467.59 2190.35
High-dependency unita 125.74 423.47 13.82 87.07 41.43 6.40 239.95 937.87
General medicinea 73.12 161.03 16.60 47.80 3.77 25.77 5.81 142.82 476.73
Inpatient (clinical oncology)a 103.47 198.66 74.87 157.15 30.71 38.25 293.77 896.88
Day case (clinical oncology)b 147.27 77.37 51.67 281.32 17.41 24.84 213.34 813.22
Outpatient (clinical oncology)c – – – – – – 192.40 59.37 251.77
a Report R040.
b Report R042.
c Report R044.
Notes
All outpatient indirect costs are included in the ‘other’ category.
Hospitalisation unit costs are based on information reported by Information Services Division Scotland 2017.37
TABLE 10 Adjuvant chemotherapy received by intervention and planned regimen (mg/patient)
Drug
All patients (N= 6065) Oxaliplatin and 5FU (N= 1971) Oxaliplatin and capecitabine (N= 4094)
3-month
treatment,
mean
6-month
treatment,
mean
Incremental
difference:
3-month vs.
6-month; p-value
3-month
treatment
6-month
treatment
Incremental
difference:
3-month vs.
6-month; p-value
3-month
treatment
6-month
treatment
Incremental
difference:
3-month vs.
6-month; p-value
Patients (n) 3035 3030 984 987 2051 2043
Oxaliplatin 842.1 1273.0 –430.8; < 0.001 875.8 1352.5 –476.7; < 0.001 826.0 1234.5 –408.5; < 0.001
Capecitabine 114,142.1 192,930.5 –78,788.4; < 0.001 3622.8 7110.4 –3487.7; 0.031 167,165.6 282,702.6 –115,537.0; < 0.001
5FU bolus 1293.9 2184.6 –890.7; < 0.001 3871.6 6391.7 –2520.1; < 0.001 57.3 152.1 –94.8; < 0.001
5FU continuous
infusion
8012.8 14,196.1 –6183.3; < 0.001 23,991.7 41,645.9 –17,654.3; < 0.001 346.6 934.7 –588.1; < 0.001
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TABLE 11 Hospital resources by intervention and planned regimen (night stay, day stay or appointment per patient)
Resource
All patients (N= 6065) Oxaliplatin and 5FU (N= 1971) Oxaliplatin and capecitabine (N= 4094)
3-month
treatment,
mean
6-month
treatment,
mean
Incremental
difference:
3-month vs.
6-month; p-value
3-month
treatment,
mean
6-month
treatment,
mean
Incremental
difference
3-month vs.
6-month; p-value
3-month
treatment,
mean
6-month
treatment,
mean
Incremental
difference:
3-month vs.
6-month; p-value
Patients (n) 3035 3030 984 987 2051 2043
0 to 3 months
Intensive care unita 0.013 0.022 –0.010; 0.222 0.006 0.020 –0.014; 0.198 0.016 0.023 –0.007; 0.475
High-dependency unita 0.017 0.029 –0.012; 0.391 0.008 0.014 –0.006; 0.520 0.022 0.037 –0.015; 0.462
General/acute medicinea 0.846 0.753 0.093; 0.230 0.758 0.661 0.098; 0.421 0.888 0.798 0.090; 0.361
Inpatient visita 0.143 0.148 –0.005; 0.859 0.186 0.209 –0.023; 0.669 0.122 0.118 0.004; 0.873
Outpatient visitb 4.588 4.633 –0.045; 0.667 6.777 6.522 0.256; 0.274 3.538 3.721 –0.183; 0.045
Day casec 2.643 2.653 –0.009; 0.919 4.254 4.193 0.062; 0.784 1.871 1.909 –0.038; 0.583
3 to 6 months
Intensive care unita 0.042 0.012 0.030; 0.119 0.013 0.018 –0.005; 0.743 0.055 0.009 0.046; 0.088
High-dependency unita 0.011 0.009 0.002; 0.785 0.006 0.017 –0.011; 0.459 0.013 0.005 0.008; 0.293
General/acute medicinea 0.524 0.203 0.321; 0.000 0.611 0.226 0.385; 0.005 0.482 0.191 0.291; 0.001
Inpatient visita 0.036 0.081 –0.045; 0.005 0.029 0.128 –0.098; 0.002 0.039 0.058 –0.020; 0.282
Outpatient visitb 2.123 3.585 –1.462; 0.000 2.408 5.200 –2.792; 0.000 1.987 2.805 –0.818; 0.000
Day casec 0.272 1.980 –1.708; 0.000 0.398 3.275 –2.876; 0.000 0.211 1.354 –1.143; 0.000
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TABLE 11 Hospital resources by intervention and planned regimen (night stay, day stay or appointment per patient) (continued )
Resource
All patients (N= 6065) Oxaliplatin and 5FU (N= 1971) Oxaliplatin and capecitabine (N= 4094)
3-month
treatment,
mean
6-month
treatment,
mean
Incremental
difference:
3-month vs.
6-month; p-value
3-month
treatment,
mean
6-month
treatment,
mean
Incremental
difference
3-month vs.
6-month; p-value
3-month
treatment,
mean
6-month
treatment,
mean
Incremental
difference:
3-month vs.
6-month; p-value
6 to 12 months
Intensive care unita 0.027 0.059 –0.032; 0.082 0.021 0.087 –0.066; 0.042 0.030 0.046 –0.015; 0.489
High-dependency unita 0.015 0.028 –0.014; 0.200 0.024 0.030 –0.006; 0.794 0.010 0.027 –0.017; 0.122
General/acute medicinea 0.842 1.353 –0.511; 0.001 1.036 1.737 –0.701; 0.024 0.749 1.168 –0.419; 0.011
Inpatient visita 0.028 0.048 –0.020; 0.147 0.048 0.048 0.000; 0.996 0.019 0.047 –0.029; 0.042
Outpatient visitb 4.071 4.566 –0.495; 0.000 4.165 4.759 –0.594; 0.001 4.027 4.473 –0.447; 0.000
Day casec 0.399 0.629 –0.230; 0.000 0.477 0.888 –0.411; 0.000 0.362 0.504 –0.142; 0.004
> 12 months
Intensive care unita 0.050 0.053 –0.003; 0.874 0.057 0.065 –0.008; 0.801 0.047 0.047 –0.000; 0.993
High-dependency unita 0.063 0.081 –0.018; 0.520 0.053 0.062 –0.009; 0.775 0.068 0.091 –0.023; 0.561
General/acute medicinea 2.317 2.474 –0.158; 0.467 2.466 2.065 0.402; 0.266 2.245 2.672 –0.427; 0.113
Inpatient visita 0.133 0.110 0.023; 0.537 0.147 0.094 0.053; 0.374 0.126 0.117 0.008; 0.859
Outpatient visitb 8.623 8.755 –0.132; 0.615 8.747 8.380 0.367; 0.442 8.563 8.936 –0.373; 0.236
Day casec 1.319 1.441 –0.121; 0.330 1.311 1.498 –0.188; 0.397 1.323 1.413 –0.089; 0.553
a Number of nights’ stay.
b Number of days.
c Number of appointments.
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The mean costs incurred by patients, broken down by hospitalisation period, are presented in Table 12. As
expected, adjuvant chemotherapy costs were higher for 6-month treatment duration (p < 0.001). Hospitalisation
costs differed between treatment groups for the 4- to 6-month period (p < 0.001); however, the data also
showed that 6-month-duration adjuvant chemotherapy was associated with higher hospitalisation costs over
the 7- to 12-month period (p = 0.030), possibly reflecting the persistence of treatment-related complications
owing to the longer treatment period. Adjuvant chemotherapy and hospitalisation costs for 6-month treatment
duration would be expected to be double those for the 3-month regimen; in reality they were 1.67 and 1.45
times higher, respectively, for the 6-month treatment group. This is because only a proportion of patients
randomised to the 6-month treatment group were able to complete the full course, owing to tolerability of the
adjuvant treatment regimens. Some patients randomised to the 6-month treatment group completed only 4 or
5 months of chemotherapy, and hence treatment and hospitalisation costs are greater, but not doubled, in the
6-month treatment group. Thereby reducing expenditure on chemotherapy agents and time spent in hospital.
Whereas 83.3% of patients randomised to 3-month treatment received full-duration therapy, only 58.8% of
those randomised to the 6-month regimen received this; this is consistent with the more frequent reporting of
AEs of diarrhoea and peripheral neuropathy leading to discontinuation. No difference in cost was seen between
treatment groups beyond 12 months. Overall, cost was significantly higher for the 6-month treatment group
(p < 0.001), being driven primarily by hospitalisation costs (–£2835) rather than the by cost of the adjuvant
chemotherapy agents (–£1829) themselves.
Cost-effectiveness
The base-case cost-effectiveness analysis showed that the 3-month adjuvant chemotherapy strategy
was significantly cheaper than the 6-month strategy, costing £4881 less over the 8-year analysis period
(Table 13). The 3-month dosing strategy also resulted in the greatest QALY gain, although this did not
reach statistical significance (p = 0.33), with uncertainty over the QALY indicated by wide 95% CIs.
QALY gains for the 3-month treatment group are driven by the significantly better HRQoL. The 3-month
treatment strategy was dominant, showing cost saving and improvement in QALYs, with an incremental
NMB of £7246 per patient.
TABLE 12 Patient costs by treatment group
Time from the start
of treatment
3-month treatment
(N= 3035), mean (£/patient)
6-month treatment
(N= 3030), mean (£/patient)
Incremental difference
3-month vs. 6-month
Mean
(£/patient) p-value
Adjuvant chemotherapy 2750 4579 –1829 < 0.001
Hospitalisation
(0 to 3 months)
3576 3595 –19 0.816
Hospitalisation
(4 to 6 months)
1790 4185 –2395 < 0.001
Hospitalisation
(7 to 12 months)
2748 3054 –306 0.030
Hospitalisation
(> 12 months)
8473 8588 –115 0.876
Total hospitalisation 16,587 19,422 –2835 < 0.001
Total 19,337 24,001 –4663 < 0.001
Note
Values refer to non-discounted average cost for each period conditional on survival.
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Figure 17 shows the cost-effectiveness acceptability curve. Three-month-duration adjuvant chemotherapy
for colorectal cancer shows 99% probability of being cost-effective at both the upper and the lower UK
decision thresholds of £30,000 and £20,000 per QALY, respectively.30 The 3-month regimen also
represents the optimal choice across a range of willingness-to-pay (WTP) values.
Cost-effectiveness was assessed for various patient subgroups (treatment regimen, level of disease risk, gender
and age), as shown in Table 14. Cost-effectiveness results were comparable for the base-case and most
subgroups, with the exceptions being oxaliplatin and 5FU treatment and male gender; 3-month treatment
was generally dominant and showed a 99% probability of being the cost-effective option. With oxaliplatin
and 5FU treatment, the 3-month treatment group showed cost savings but had fewer QALY gains, which
was driven by a slightly higher life expectancy in the 6-month treatment group. A relative QALY advantage
for 3-month treatment was seen for oxaliplatin and capecitabine chemotherapy, high-risk disease, female
patients and older patients. An interaction test of differences in incremental QALYs between subgroups
concluded that only in the case of the chemotherapy regimen was there a statistically significant difference in
QALYs between the 3-month and 6-month treatment groups, amounting to 0.19 QALY gains for oxaliplatin
TABLE 13 Cost estimates and quality-adjusted life-years by treatment group
Intervention
strategy
Cost (£/patient),
mean (95% CI)
Life expectancy,
mean (95% CI)
QALYs,
mean (95% CI)
NMB (Cost/QALY)
(£), mean (95% CI)
Probable cost-
effectiveness,
λ= £30,000
3-month
treatment
18,401
(17,538 to 19,328)
6.87
(6.73 to 6.99)
5.30
(5.17 to 5.40)
140,492
(135,327 to 145,658)
0.995
6-month
treatment
23,282
(22,227 to 24,367)
6.90
(6.78 to 7.02)
5.22
(5.10 to 5.34)
133,246
(129,569 to 136,922)
0.005
Incremental
difference,
3-month vs.
6-month
–4881
(–6269 to –3492)
–0.03
(–0.22 to 0.13)
0.08
(–0.086 to 0.230)
7246
(3469 to 11,023)
3-month
dominant
Notes
Health utilities conditional on survival considered. Kaplan–Meier survival analysis estimator and partitioned survival analysis
were used for costs and QALYs, respectively. CIs were computed using bootstrap sampling. Probability of cost-effectiveness
was calculated using 1000 bootstrap replications.
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FIGURE 17 Cost-effectiveness acceptability curve: base-case analysis.
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TABLE 14 Cost estimates and QALYs for patient subgroups
Intervention
strategy
Cost per
patient (£),
mean (95% CI)
Life expectancy,
mean (95% CI)
QALYs,
mean (95% CI)
NMB
(£30,000/QALY),
mean (95% CI)
Probability cost-
effectiveness
λ= £30,000
Oxaliplatin and capecitabine
3-month
treatment
17,650
(16,668 to 18,919)
6.90
(6.75 to 7.04)
5.34
(5.17 to 5.48)
142,500
(136,469 to 148,531)
0.999
6-month
treatment
21,503
(20,389 to 22,723)
6.83
(6.67 to 7.99)
5.16
(5.00 to 5.32)
133,253
(128,206 to 138,300)
0.001
Incremental
difference
–3,853
(–5487 to –2030)
0.07
(–0.13 to 0.30)
0.19
(–0.001 to 0.38)
9247
(4178 to 14,315)
3-month
dominant
Oxaliplatin and 5FU
3-month
treatment
19,641
(18,477 to 20,774)
6.83
(6.57 to 7.03)
5.21
(4.99 to 5.39)
136,679
(128,249 to 145,108)
0.772
6-month
treatment
26,483
(24,659 to 28,292)
7.05
(6.87 to 7.23)
5.33
(5.15 to 5.51)
133,449
(127,107 to 139,791)
0.228
Incremental
difference
–6841
(–9040 to –4756)
–0.22
(–0.52 to 0.03)
–0.12
(–0.38 to 0.13)
3229
(–2494 to 8953)
High risk
3-month
treatment
19,057
(17,888 to 20,339)
6.31
(6.11 to 6.52)
4.84
(4.46 to 5.03)
126,450
(118,973 to 133,927)
0.997
6-month
treatment
24,815
(23,481 to 26,362)
6.36
(6.15 to 6.54)
4.71
(4.53 to 4.87)
116,477
(110,700 to 122,254)
0.003
Incremental
difference
–5758
(–7686 to –3924)
–0.05
(–0.32 to 0.24)
0.13
(–0.08 to 0.37)
9972
(4664 to 15,281)
3-month
dominant
Low risk
3-month
treatment
17,671
(16,596 to 18,925)
7.39
(7.25 to 7.52)
5.72
(5.58 to 5.85)
153,997
(147,785 to 160,208)
0.922
6-month
treatment
21,422
(20,305 to 22,573)
7.41
(7.28 to 7.53)
5.71
(5.55 to 5.85)
149,816
(145,425 to 154,206)
0.078
Incremental
difference
–3751
(–5402 to –2153)
–0.02
(–0.20 to 0.17)
0.01
(–0.17 to 0.21)
4180
(–429 to 8791)
3-month
dominant
Female
3-month
treatment
17,741
(16,408 to 18,934)
6.92
(6.74 to 7.08)
5.30
(5.13 to 5.47)
141,617
(133,821 to 149,413)
0.997
6-month
treatment
22,228
(20,716 to 23,936)
6.78
(6.59 to 6.94)
5.10
(4.92 to 5.27)
130,893
(125,233 to 136,553)
0.003
Incremental
difference
–4487
(–6518 to –2637)
0.14
(–0.11 to 0.39)
0.20
(–0.03 to 0.44)
10,723
(4880 to 16,567)
3-month
dominant
continued
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and capecitabine and –0.12 QALY gains for oxaliplatin and 5FU (p = 0.066). This relative advantage of 6-month
treatment duration with oxaliplatin and 5FU was driven by the longer life expectancy gain (0.22 years vs.
–0.007 years, interaction test p = 0.106). In the oxaliplatin and 5FU subgroup, 3-month treatment maintained
a greater NMB, with an incremental NMB compared with 6-month treatment of £3229 and a 77% probability
of being cost-effective. Therefore, although 3-month treatment with oxaliplatin and 5FU is associated with
a slightly lower life expectancy, it remains the optimal treatment strategy. An interaction test of differences
in incremental QALYs between the disease risk, gender and age subgroups showed no significant
differences in incremental QALYs.
Figure 18 presents the cost-effectiveness acceptability curves for each of the subgroup analyses.
For each subgroup, the 3-month strategy had the highest probability of being cost-effective over a
wide range of WTP values. Only when a threshold higher than £60,000/QALY was considered did
the 6-month regimen become the cost-effective strategy (with highest probability) for the oxaliplatin
and 5FU treatment group.
TABLE 14 Cost estimates and QALYs for patient subgroups (continued )
Intervention
strategy
Cost per
patient (£),
mean (95% CI)
Life expectancy,
mean (95% CI)
QALYs,
mean (95% CI)
NMB
(£30,000/QALY),
mean (95% CI)
Probability cost-
effectiveness
λ= £30,000
Male
3-month
treatment
18,857
(17,737 to 20,098)
6.83
(6.63 to 7.03)
5.28
(5.11 to 5.43)
139,377
(132,810.1 to 145,944)
0.912
6-month
treatment
23,695
(22,531 to 24,930)
6.98
(6.82 to 7.13)
5.29
(5.15 to 5.83)
135,055
(130,064 to 140,046)
0.088
Incremental
difference
–4837
(–6613 to –3011)
–0.15
(–0.40 to 0.09)
–0.02
(–0.22 to 0.18)
4321
(–351 to 8994)
≥ 65 years
3-month
treatment
19,364
(18,101 to 20,831)
6.73
(6.57 to 6.89)
5.24
(5.10 to 5.39)
137,918
(131,146 to 144,689)
0.985
6-month
treatment
23,839
(21,981 to 24,917)
6.72
(6.52 to 6.87)
5.13
(4.98 to 5.27)
130,294
(125,355 to 135,234)
0.015
Incremental
difference
–4474
(–5994 to –2090)
0.01
(–0.22 to 0.27)
0.11
(–0.09 to 0.32)
7623
(2789 to 12,457)
3-month
dominant
< 65 years
3-month
treatment
17,572
(16,431 to 18,672)
7.01
(6.83 to 7.17)
5.35
(5.18 to 5.50)
142,872
(135,713 to 150,032)
0.977
6-month
treatment
23,066
(21,838 to 24,435)
7.09
(6.94 to 7.24)
5.29
(5.12 to 5.46)
135,670
(130,541 to 140,799)
0.023
Incremental
difference
–5493
(–7297 to –3870)
–0.08
(–0.32 to 0.14)
0.05
(–0.17 to 0.28)
7202
(1609 to 12,795)
3-month
dominant
Notes
Health utilities conditional on survival considered. Kaplan–Meier survival analysis estimator and partitioned survival analysis
were used for costs and QALYs, respectively. CIs were computed using bootstrap sampling. Probability of cost-effectiveness
was calculated using 1000 bootstrap replications.
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FIGURE 18 Cost-effectiveness acceptability curves: subgroup analysis. (a) Treatment: CAPOX; (b) treatment: FOLFOX;
(c) risk: high; (d) risk: low; (e) gender: female; (f) gender: male; (h) age: ≥ 65 years; and (i) age: < 65 years.
CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU. (continued )
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FIGURE 18 Cost-effectiveness acceptability curves: subgroup analysis. (a) Treatment: CAPOX; (b) treatment: FOLFOX;
(c) risk: high; (d) risk: low; (e) gender: female; (f) gender: male; (h) age: ≥ 65 years; and (i) age: < 65 years.
CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU.
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Chapter 5 Discussion
T reatment with oxaliplatin and fluoropyrimidine is the usual adjuvant chemotherapy regimen for patientswith high-risk stage II or stage III colorectal cancer,5,9 with 6-month treatment duration being the accepted
standard. However, oxaliplatin administration is associated with cumulative toxicity that is often characterised
by chronic and often irreversible neuropathy.6,7 Because the toxicity of oxaliplatin/fluoropyrimidine regimens
is cumulative, reducing the duration of adjuvant treatment could potentially ameliorate such effects.11 The
SCOT clinical trial was conducted to determine whether or not reducting the duration of administration of
oxaliplatin and fluoropyrimidine adjuvant chemotherapy from 6 months to 3 months is likely to compromise
efficacy; the study also considered the effect of reducing treatment duration on toxicity, HRQoL and health
economic parameters. It is our understanding that the SCOT study is the largest single randomised study of
infusional adjuvant treatment for colorectal cancer to date.
Efficacy assessment
The SCOT study was designed to demonstrate that 3 months of adjuvant oxaliplatin-containing
chemotherapy treatment was non-inferior to 6 months of treatment when used to treat patients with
high-risk stage II or stage III colorectal cancer. The non-inferiority boundary was set to exclude a maximum
2.5% decrease in 3-year DFS comparing the 3-month and 6-month treatment groups; based on previous
trials, this would result in an estimated 3-year DFS rate of 78%. The value of 2.5% was chosen because it was
half of the difference in 3-year DFS seen in the MOSAIC study6 when comparing the oxaliplatin-containing
treatment and fluoropyrimidine only.6 Clinicians who routinely treat colorectal cancer considered that this
represents a small difference and would be ‘an acceptable pay-off’ for a significant reduction in the sequalae
associated with persistent neuropathy and the potential for HRQoL improvements in patients for whom this
treatment approach proved curative. This difference corresponds to a HR of 1.13, and it was planned that this
would be detected with 90% power at the 2.5% one-sided statistical-significance level.
The study protocol planned for the recruitment of 9500 patients who were expected to experience a total
of 2750 DFS events over the course of the trial. However, owing to problems with recruitment, a total
of 6088 patients were randomised to study treatment and experienced 1482 events, thereby reducing
the statistical power to demonstrate an effect to 66%. Despite this limitation, the trial successfully
demonstrated that 3-month oxaliplatin-based adjuvant chemotherapy was non-inferior to 6 months of
treatment (pNI = 0.012) across the overall trial population (patients with high-risk stage II or stage III cancer
of the colon or rectum); 3-year DFS rates were 77.1% of patients (SE = 0.8%) for 6-month treatment and
76.7% of patients (SE = 0.8%) for 3-month treatment, resulting in a HR of 1.006 (95% CI 0.909 to
1.114). The 3-year DFS rate seen for the 6-month treatment group in this study was similar to that seen
with 6 months of oxaliplatin-containing adjuvant chemotherapy in the MOSAIC6 and NSABP C-077 studies
(78.2% and 76.1%, respectively), suggesting that the outcome observed in our ‘control’ group was
comparable to previous findings.6,7 The absolute reduction in 3-year DFS rate seen with 3-month treatment
was 0.4% (SE = 1.1%).
Sensitivity analyses of DFS rate were conducted based on the actual duration of treatment that patients
received. These analyses did not show non-inferiority for 3-month adjuvant chemotherapy but were inherently
biased by the differential exclusion of patients not able to receive prolonged therapy because of the different
target treatment durations for the treatment groups. In a setting such as this, where differential compliance is
intrinsic to the treatments being compared, the ITT analysis is likely to represent a more appropriate reflection
of the effect of the intervention.
It is important to note that the proportion of patients randomised with stage II disease (as opposed to
stage III) was lower than seen in previous trials (18.3% vs. 40% in the MOSAIC trial and 30% in the
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NASBP C-07 trial); the SCOT study recruitment, however, was restricted to patients with high-risk stage II
disease, whereas the patients in the MOSAIC trial and the NASBP C-07 trial had all-risk stage II disease.
The SCOT trial included a lower proportion of patients with stage II disease, which could lead to criticism
that the trial populations had different baseline prognoses. However, because the forest plots did not
identify dependence of the effect of duration of adjuvant chemotherapy on N-stage or T-stage disease,
or between patients with high-risk stage II versus stage III disease, this indicates that effect of duration is
not a real concern. It should be noted that, in many parts of the world, clinical practice for patients with
high-risk, stage II disease or stage III disease (especially if over 70 years of age) involves single-agent
fluoropyrimidine administered over 6 months, as the addition of oxaliplatin to the regimen for these
patients has not been shown to improve survival.42 The results of this trial do not provide information on
duration of therapy for patients managed with single-agent fluoropyrimidine.
At the time the SCOT study started few data were available concerning the use of adjuvant chemotherapy
for rectal cancer, as many adjuvant-treatment studies exclude these patients. Patients with rectal cancer
were eligible to participate in the SCOT study if they had not received preoperative chemotherapy (short-
course radiotherapy alone was allowed) and had undergone total mesorectal excision with an R0 resection.
Forest plots did not appear to show any differences in the effect of duration of adjuvant chemotherapy
when comparing patients with rectal and patients with colon cancer. Although definitive conclusions about
the effect of treatment duration could not be drawn for patient subgroups from the SCOT trial, as a result
of the small size of many subgroups and fewer numbers of DFS events, the results do raise important
questions about how to manage patients with rectal cancer. Data from the SCOT study suggest that
3-month oxaliplatin-containing adjuvant chemotherapy could be considered for rectal cancer patients
requiring adjuvant therapy.
This study did not attempt to address the potential impact of various other prognostic factors on the
efficacy of standard or short duration oxaliplatin-based adjuvant chemotherapy, such as the sidedness of
the cancer; RAS and BRAF status, which are known to have an impact on the prognosis of patients with
metastatic disease; and microsatellite instability status.43 These questions cannot be currently answered by
the results of the SCOT study, but the findings of an ongoing translational-research substudy (TransSCOT)
will provide more information.
Chemotherapy regimen
The results of both the SCOT study and data pooled for the IDEA collaboration44 indicate that the effectiveness
of 3 months of adjuvant chemotherapy may depend on the choice of chemotherapy regimen. When the
effect of duration was assessed for the two chemotherapy regimens specified for the trial (oxaliplatin and
capecitabine and oxaliplatin and 5FU), clear non-inferiority in terms of DFS was demonstrated for patients
receiving oxaliplatin and capecitabine for 3 months compared with 6 months of treatment (HR 0.94, 95% CI
0.84 to 1.07; pNI = 0.002); non-inferiority was not demonstrated when comparing patients receiving
oxaliplatin and those receiving 5FU (HR 1.16, 95% CI 0.96 to 1.39; pNI = 0.591). The reasons for this are
not clear.
Achieving full-duration adjuvant chemotherapy treatment over 6 months is more difficult than over
3 months. In this study, 83.3% of patients randomised to 3-month adjuvant chemotherapy continued with
the regimen for the planned duration; only 58.8% of those randomised to 6-month adjuvant chemotherapy
continued for the planned duration. However, compliance data showed that 94–98% of patients in the
3-month treatment group and 82–85% in the 6-month treatment group were administered the full
planned fluoropyrimidine dose depending on regimen choice; corresponding figures for oxaliplatin were
96–98% for the 3-month treatment group and 69–73% for the 6-month treatment group. As similar
proportions of patients received the full planned doses of the individual chemotherapeutic agents for the
two treatment groups, poor treatment compliance is unlikely to explain the difference in the duration effect
between the two regimens. It should be noted that capecitabine is an oral drug that is self-administered at
home and these assessments are based on the prescribed dose, and so detailed compliance data are not
available. This could potentially have led to an underestimation of the dose intensity for patients receiving
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oxaliplatin and capecitabine. However, this is considered unlikely as compliance with oral chemotherapy
treatments is usually high.
The chemotherapy regimen that individual patients received was not randomised but rather was selected
by the physician/patient. Thus, the particular chemotherapy combination may have been chosen due to
particular patient characteristics; or there could be a real difference between the 3-month and 6-month
regimens in the adjuvant setting.
l There may have been clinical reasons why a particular chemotherapy regimen was selected for
an individual patient. For example, clinicians may have selected the oxaliplatin and capecitabine
combination for patients who were perceived as frail in order to avoid the risk of neutropenic sepsis
inherent with oxaliplatin and 5FU; similarly, the starting dose of capecitabine may have been reduced
because of perceived frailty. However, some clinicians specifically avoid giving capecitabine to older
patients because of the risks associated with this agent in those with impaired renal function. In this
study, the reasons for selecting a particular adjuvant chemotherapy regimen for individual patients are
not known.
l Alternatively, there may be real differences between treatment regimens associated with exposure to
the component agents. For the oxaliplatin and capecitabine regimen, the oxaliplatin dose administered
in each cycle is higher than that for oxaliplatin and 5FU; therefore, it can be presumed that higher peak
exposure may be achieved. Two previous studies suggest that peak oxaliplatin concentration is key to
clinical effect, which would be likely to favour the oxaliplatin and capecitabine regimen.45,46 In addition,
peak fluoropyrimidine exposure to is likely to be lower but the continuity of exposure is greater when
fluoropyrimidine is given twice daily for 2 out of 3 weeks (compared with 5FU, which is given as bolus
and then over 2 days every 2 weeks); if cells are cycling through S-phase sporadically, the greater
continuity of fluoropyrimidine exposure with the capecitabine regimen could mean that there is a
greater chance that tumour cells will be exposed at a critical phase in the cell cycle. It could be that
micrometastatic disease is rendered more sensitive because of one or both of these differences.
Disease stage
Stage III colorectal cancer is a heterogeneous disease group; data from the IDEA collaboration and from
multiple adjuvant trials have shown that patients with T1–3, N1 pathology have much better outcomes
than those with either T4 or N2 features.44 This has led to the evolution of the concept of high-risk (with
either T4 or N2 disease) and low-risk (with T1–3, N1 disease) stage III patient populations. To optimally
treat stage III colorectal cancer, it may be necessary to treat these groups in different ways. The SCOT
study has similarly demonstrated that patients with T1–3, N1 disease have better 3-year DFS than those
with either T4 or N2 pathology, but it did not show a difference in duration effect between these groups
when this was assessed using a test for heterogeneity. Nonetheless, 3-month chemotherapy was clearly
non-inferior for patients with T1–3, N1 colorectal cancer (HR 0.91, 95% CI 0.75 to 1.10). For patients
with T4 and/or N2 pathology, outcomes were poorer when they received 3 months of treatment; the
non-inferiority of this treatment duration in terms of DFS was not seen in this group of patients in the
SCOT study (HR 1.07, 95% CI 0.94 to 1.22). The HR was > 1 for the 3-month compared with the 6-month
duration, suggesting some loss of efficacy. However, the wide CIs mean that this result could reflect a
wide spectrum of possible effects, from a small potential benefit with 3-month treatment to decreased
efficacy beyond the non-inferiority boundary. It is important to note that the observed absolute reduction
in 3-year DFS between the 3-month and the 6-month treatment groups was only 1.9%. Although non-
inferiority was not formally met for high-risk stage III patients, in view of the small absolute difference in
3-year DFS the benefits of longer treatment duration need to be carefully balanced against the increased
risk of cumulative chronic toxicity.
Some text in this paragraph is taken from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is
an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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Among patients with T4 or N2 disease, the absolute increase in 3-year DFS rate comparing 6-month with
3-month treatment was 2.8% (95% CI –4.1% to 9.7%) for oxaliplatin and 5FU and 1.3% (95% CI –3.7%
to 6.2%) for oxaliplatin and capecitabine (see Figure 8). In view of the difference in toxicity seen with
longer duration treatment, patients are likely to accept a small reduction in DFS in exchange for reduced
toxicity; this is especially true if they are able to receive oxaliplatin and capecitabine. There is less evidence
to support use of short-duration adjuvant treatment if it is decided that the patient needs to receive
oxaliplatin and 5FU or has T4 disease.
Safety and toxicity
To our knowledge, this is the largest randomised study of adjuvant chemotherapy for colorectal cancer
and confirms the findings of previous studies by showing that oxaliplatin-based combination chemotherapy
can be safely delivered, with a mortality rate of 0.5%.6,47 The most common grade 3/4 side effects reported
were peripheral neuropathy, diarrhoea, neutropenia, fatigue, pain, nausea and hand–foot syndrome, also
consistent with previous studies. Although 12% of patients overall had grade 3/4 neutropenia, only 1.2% had
febrile neutropenia; the febrile neutropenia rate in the MOSAIC study was 1.8%.6
Some text in this paragraph is taken from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is
an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
The SCOT study results show that 6 months of adjuvant chemotherapy is associated with significantly
greater toxicity than 3 months of treatment. This difference was most apparent for peripheral neuropathy,
with 58% of patients in the 6-month treatment group reporting grade ≥ 2 neuropathy compared with
25% of patients in the 3-month treatment group. Peripheral neuropathy, as reported via a patient
questionnaire, was significantly worse in the 6-month treatment group and persisted for ≥ 5 years. Other
AEs that are important to patients, such as diarrhoea and hand–foot syndrome, were also significantly
more common in patients undergoing 6 months of treatment. Our conclusions regarding long-term
neuropathy consequences need to be interpreted in the light of a substantial number of missing data.
However, the treatment effect and significance levels are substantial, with no evidence of bias between
the treatment groups, and the analysis approach was adapted to make allowance for missing data.
The effects of toxicity early in treatment are important; in the SCOT study, 14% of patients in each group
did not complete 3 months of treatment. A similar proportion (13%) of those stopping treatment in the
first 3 months in an adjuvant study using oxaliplatin and capecitabine was reported in 2007.47 Although
the choice of chemotherapy was not randomised, in the SCOT study a greater proportion of patients
receiving oxaliplatin and capecitabine (15%) appeared to stop treatment before 3 months than estimated
for those receiving oxaliplatin and 5FU (11%).
Achieving full-duration adjuvant chemotherapy treatment over 6 months is more difficult than over
3 months. In this study, 83.3% of patients randomised to 3-month adjuvant chemotherapy continued with
the regimen for the planned duration, whereas only 58.8% of those randomised to 6-month adjuvant
chemotherapy continued for the planned duration. Problems with delivering 6 months of therapy were
most pronounced for the oxaliplatin component, where the median percentage of full dose delivered was
96.6% for the 3-month treatment group as compared with 70.2% for the 6-month treatment group.
Fluoropyrimidine treatment was not compromised to the same extent, with the median percentage of full
doses delivered being 95.3% and 83.2% for the 3-month and 6-month treatment groups, respectively.
As expected, there was a difference in the toxicity profile according to fluoropyrimidine backbone, with
more grade 3/4 neutropenia in those receiving oxaliplatin and 5FU (23% vs. 5%) and more grade
3/4 diarrhoea in those receiving oxaliplatin and capecitabine (15% vs. 9%). The frequency of these
toxicities is consistent with those reported in other studies of adjuvant treatment.6,47
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Peripheral neuropathy
The only chronic toxicity seen in the SCOT study was sensory peripheral neuropathy, which occurred
with significantly lower frequency in the 3-month treatment group than in the 6-month treatment
group (overall grade 3/4 toxicity was 4.1% in the 3-month treatment group compared with 16.5% in
the 6-month treatment group). The study therefore met its aim of achieving a > 50% reduction in the
incidence of grade 3/4 peripheral neuropathy by administering treatment over 3 months. The frequency of
peripheral neuropathy reported here is higher than seen for 6-month adjuvant treatment in the MOSAIC,
NSABP C-07 and XELOXA trials (12.4%, 8.2% and 11%, respectively).6,7,47 Peripheral neuropathy in the
SCOT study was assessed by the investigator using NCI CTCAE (version 3), which grades the condition on
a scale of 0–4; neuropathy in the MOSAIC study was graded using NCI CTCAE (version 1), in the NSABP
C-07 study using the NCI-Sanofi Neurosensory score (graded from 0–3) and in the XELOXA study using
NCI CTCAE (version 3). As peripheral neuropathy has become recognised as the main dose-limiting toxicity
with oxaliplatin, clinicians may be questioning patients more closely about such symptoms in more recent
trials. The incidence and course of acute and chronic peripheral neuropathy as a result of oxaliplatin has
been well documented using a comprehensive PRO measure (EORTC QLQ-CIPN 20).11 This study showed
that the incidence and severity of sensory peripheral neuropathy increases with the number of cycles of
adjuvant chemotherapy received, in broad agreement with the findings of this study.
In the SCOT study, patients were administered either oxaliplatin and capecitabine or oxaliplatin and 5FU
in a non-randomised manner. Although the cumulative oxaliplatin dose is similar for the two regimens
(1040 mg/m2 and 1020 mg/m2, respectively), the individual doses of oxaliplatin are higher with oxaliplatin
and capecitabine (130 mg/m2 every third week compared with 85 mg/m2 every second week with
oxaliplatin and 5FU). However, the rates of grade ≥ 2 peripheral neuropathy were similar irrespective of
the fluoropyrimidine backbone for both the 3-month (21.3% with oxaliplatin and 5FU and 25.7% with
oxaliplatin and capecitabine) and the 6-month (57.7% and 58.1%) groups.
In this study, some of the patients who were randomised to receive either 3- or 6-month duration of
adjuvant chemotherapy had persistent neuropathy over ≥ 5 years, with neuropathy frequency being
significantly higher (p < 0.001) at 3, 4 and 5 years for those randomised to the 6-month duration treatment.
The level of chronic peripheral neuropathy seen in the SCOT study is in line with that previously reported
18 months after treatment using EORTC QLQ-CIPN 20,48 with 50% of patients reporting < 10% reduction
in sensory neuropathy scores and 19% reporting > 30% reduction in sensory neuropathy scores compared
with baseline.11
The MOSAIC6 and the NSABP C-077 studies showed rates of grade 3 neuropathy reported at 1 year of
1.1% and 0.6%, respectively. It is now recognised that persistent peripheral neuropathy is a major side
effect for patients who have received oxaliplatin, especially in the adjuvant setting. For the majority of
these patients neuropathy is a significant problem; because of this, it may be better detected using a
more in-depth PRO measure such as the FACT/GOG-Ntx4 questionnaire rather than grading it using the
NCI CTCAE.
Health-related quality of life
Health-related quality of life (measured using QLQ-C30 Global Health Status and EQ-5D-3L) declined while
patients were receiving adjuvant chemotherapy. HRQoL was, therefore, reduced for longer in patients
randomised to receive 6-month treatment compared with 3-month treatment. HRQoL improved after
stopping treatment and within 1 year there were no clinically important differences between the two
treatment groups. EQ-5D health status, assessed using both the self-rated visual analogue scale and the
EQ-5D-3L utility index, did not differ between 9 months and the 7-year follow-up based on the minimal
clinically important differences for health utilities in cancer.23
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Health-related quality of life and peripheral neuropathy
It is accepted that clinician assessment of neuropathy using methods such as the CTCAE criteria are less sensitive
than PRO tools such as the FACT/GOG-Ntx4 or the EORTC QLQC CIPN 20.49 In this study, we supplemented the
CTCAE analyses with specific assessment of peripheral neuropathy using the FACT/GOG-Ntx4.
Health-related quality of life appeared to recover within 1 year of starting treatment; however, chronic sensory
peripheral neuropathy persisted for ≥ 5 years. Patients who recorded a greater degree of neuropathy symptoms
had significantly worse HRQoL at 12, 36 and 60 months than those with lesser symptoms. These differences
in HRQoL reached at least minimal clinically important levels. Similar findings were reported for a Dutch
study, in which there was a correlation between neuropathy symptoms and HRQoL for the 10% of patients
with the worst neuropathy symptoms (as measured by the EORTC QLQ-CIPN 20), with a reduction in the
HRQoL scores (as measured by the QLQ-C3020) from 2 to 11 years after oxaliplatin treatment for colorectal
cancer.50 It appears that a lack of an overall difference in HRQoL scores does not reflect the meaningful
differences experienced by patients with the worst long-term, chronic, neuropathy.
Health economic assessment
The results of the economic evaluation showed that a 3-month duration adjuvant regimen is cheaper and a
dominant strategy for chemotherapy treatment for patients with high-risk, stage II or stage III colorectal
cancer. The shorter treatment duration significantly reduced costs related to adjuvant chemotherapy
administration and hospitalisation. The 3-month treatment group showed significantly better patient HRQoL
during the treatment period, with no significant impact on overall survival, leading to an overall QALY gain
that did not reach statistical significance. The probabilistic analysis and exploration of cost-effectiveness
acceptability showed little uncertainty in the economic results over a wide range of WTP thresholds.
Four subgroup analyses came to similar conclusions, with the 3-month treatment group being the
dominant or cost-effective strategy given a £30,000 cost per QALY threshold. The type of chemotherapy
administered showed the greatest subgroup affect on cost-effectiveness. The interaction between planned
treatment and QALY differences between the two treatment groups was statistically significant. With
oxaliplatin and 5FU chemotherapy, the 6-month treatment group generated more QALYs than seen for
the 3-month treatment group, which were primarily driven by longer estimates of disease-free and overall
survival. HRQoL differences between groups favoured 3-month treatment but the survival gains for the
6-month oxaliplatin and 5FU regimen were relevant over the 8-year follow-up period, resulting in an
overall QALY gain. Nonetheless, at a decision threshold of £30,000/QALY the NMB was larger for 3-month
treatment (incremental gain of £3229 per patient) and, therefore, the 6-month duration treatment would
not be considered cost-effective from a UK perspective.30
Modelling an 8-year patient follow-up period allowed exploration of cost-effectiveness outcomes over this
longer time period. Key cost differences occurred within the first year after randomisation, where 6-month
treatment was nearly twice the cost of 3-month chemotherapy when including associated hospitalisations.
When considering years 1 to 8 there were minimal differences in hospitalisation costs between groups;
however, over the entire 8-year analysis period the total costs per patient were significantly different and
favoured 3-month treatment. Differences in costs between the treatment groups over an even longer term
would not be expected, with extrapolation beyond 8 years being unlikely to change outcomes unless there
were substantial differences in survival rate. The 8-year follow-up also allows thorough consideration of
the QALY results, which are driven by event timing. The small differences in life expectancy are subject to
uncertainty in both the base-case and subgroup analyses, yet the overall HRQoL is consistently higher for
the 3-month treatment group across all analyses. The maximum benefit in terms of HRQoL is seen 3 to
6 months after randomisation, at which time patients receiving 3-month duration chemotherapy have
stopped treatment. The negative impact on HRQoL for the 6-month treatment group is accounted for by
chemotherapy-related AEs.33
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
Study context
The SCOT trial is part of a wider initiative, the IDEA collaboration, which aims to consolidate the results
from all trials being conducted worldwide (SCOT, TOSCA,51 IDEA France,52 CALGB/SWOG 80702, ACHIEVE,53
and HORG54) that are attempting to address whether or not the duration of oxaliplatin-based adjuvant
chemotherapy can be reduced to 3 months for patients with stage III colon cancer.14 The results of the
SCOT trial are consistent with those from the IDEA collaboration in indicating that the relative effect of
shortening the duration of adjuvant chemotherapy may depend on the choice of chemotherapy regimen
(oxaliplatin and 5FU vs. oxaliplatin and capecitabine; p = 0.069 heterogeneity in the SCOT study).55 When
the effect of duration was considered separately for each regimen, oxaliplatin and capecitabine showed
non-inferiority for 3-month treatment in terms of DFS when compared with 6-month duration adjuvant
chemotherapy; for reasons that are not clear, this was not the case for oxaliplatin and 5FU adjuvant
chemotherapy. The choice of chemotherapy was not randomised but was chosen by the physician and
patient, with the reasons for selection of a particular regimen being unknown.
Limitations of the study
Some text in this paragraph is taken from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is
an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
The SCOT study was underpowered owing to issues with recruitment, which meant that fewer patients
than planned participated in the trial. However, the 95% CIs for the HR for the primary analysis lay below
the non-inferiority boundary and the results were consistent with those of individual studies conducted
within the IDEA group, particularly when considering how the duration effect depended on treatment
regimen and disease risk. This consistency with other studies indicates that the results of the SCOT
study are unlikely to represent a false-positive, in terms of showing non-inferiority. The concept that
underpowered studies are more likely to produce false-positives (ignoring the factor of publication bias,
which does not apply to a large scale enterprise such as the SCOT study) is disputed.56
Despite the size of the SCOT study, there are limitations to the reliability of the conclusions that can be
drawn for some patient subgroups. In particular, the SCOT study and the IDEA results indicate that the
duration effect differs according to the non-randomised choice of oxaliplatin and 5FU and oxaliplatin and
capecitabine chemotherapy; although non-inferiority could be shown for oxaliplatin and capecitabine, the
results for oxaliplatin and 5FU are less conclusive. Examination of results within the two stage III risk groups
(T1–3, N1 and T4 or N2) are similarly compromised.
Some limitations were also associated with the cost-effectiveness analyses presented, which generally
relate to the need for data censoring given the minimum 3-year follow-up and relatively high survival
rates (in the region of 75% after 8 years). The cost and quality-adjusted survival methodology used
(Kaplan–Meier sample average and partitioned survival analysis, respectively) were chosen to reduce
censoring-related bias. Lifetime extrapolation was not undertaken for the base-case within trial analysis
given the non-inferiority of overall survival and DFS, and dominance of the 3-month treatment group.
However, a lifetime analysis may improve the evidence for subgroup analyses where non-inferiority
criterion were not met and the dominance conclusion was subject to uncertainty. Future work will explore
lifetime analyses for the subgroups.
It should be noted that, although the SCOT study results are applicable to all patients who might be
considered for 6 months of adjuvant combination chemotherapy with oxaliplatin and fluoropyrimidine,
there are patients who are currently treated with 6 months of adjuvant fluoropyrimidine only (some
patients with high-risk stage II disease or older patients with stage III disease). The SCOT study results are
not applicable to patients receiving single agent fluoropyrimidine.
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Chapter 6 Conclusions
The SCOT study achieved its primary end point for the overall trial population, showing that 3 monthsof oxaliplatin-containing adjuvant chemotherapy is non-inferior to 6 months of the same regimen.
Three-month oxaliplatin-based chemotherapy should, therefore, be considered as an adjuvant regimen,
particularly to oxaliplatin and capecitabine combination therapy. As the study recruited 6088 patients with
conventionally defined high-risk stage II and stage III colorectal cancer from a large number of centres and
countries and made use of standard chemotherapy regimens, the study findings are applicable to a typical
patient with colorectal cancer who needs adjuvant chemotherapy treatment.
Although 3-month treatment with oxaliplatin and capecitabine was statistically non-inferior to 6-month
treatment, the study did not demonstrate with statistical certainty non-inferiority for the 3-month
oxaliplatin and 5FU regimen. Similarly, for patients with T1–3, N1 disease, the SCOT study demonstrated
non-inferiority for 3-month adjuvant treatment; however, for patients with T4 or N2 pathology, a small
absolute decrease in 3-year DFS was seen with 3-month duration treatment for both the oxaliplatin and
capecitabine and the oxaliplatin and 5FU regimens. In both cases, these absolute differences are small with
wide CIs. Therefore, in young, fit patients with very poor prognosis, a more aggressive approach, with
longer treatment duration, might be appropriate.
The SCOT results are supported by the IDEA collaboration, which also showed that the effect of duration
of adjuvant treatment was influenced by the choice of chemotherapy regimen and was similarly dependent
on whether the patient had low- or high-risk stage III disease.
Some text in this paragraph are taken from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is
an Open Access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Six-month treatment is associated with a considerable increase in toxicity compared with 3-month
treatment. The toxicity profiles of the oxaliplatin and capecitabine and oxaliplatin and 5FU regimens differ,
with diarrhoea and hand–foot syndrome more common with capecitabine and neutropenia more common
with 5FU. This study confirmed that patients receiving 6-month duration treatment experience significantly
greater acute and chronic neurotoxicity, with chronic neurotoxicity persisting to ≥ 5 years. Patients with the
worst chronic neuropathy had significantly poorer HRQoL. Neuropathy is, therefore, a significant chronic
side effect of oxaliplatin therapy for patients receiving 6 months of adjuvant chemotherapy. In view of
the increased toxicity seen with longer therapy and the consequential effects on long-term HRQoL,
there should always be a discussion with the individual patient about the most appropriate duration
of treatment, balancing the potential for longer treatment to achieve small efficacy benefits with the
likelihood of increased toxicity and poorer HRQoL. The final decision on treatment duration and regimen
for each individual will depend on a careful discussion between the clinician and patient, taking into
account the risk of recurrence, the likely absolute difference in DFS and risk of long-term toxicity, and the
strength of evidence for that particular disease context available from both the SCOT study and the wider
IDEA analysis.
This study found that, compared with traditional 6-month adjuvant chemotherapy, the 3-month treatment
strategy costs significantly less and has no significant detrimental impact on patient outcome (HRQoL and
survival). The 3-month regimen was found to dominate 6-month adjuvant chemotherapy for patients with
high-risk stage II or stage III colorectal cancer. Cost-effectiveness is affected by the type of chemotherapy
regimen used; however, the 3-month strategy was the optimal choice for both the oxaliplatin and capecitabine
and the oxaliplatin and 5FU regimens based on relevant WTP thresholds. This economic evaluation adds to the
evidence showing that 3-month treatment is not only cost-effective but also dominant over the current
standard of 6-month treatment; little uncertainty is associated with this conclusion, which supports the
economic case that 3-month treatment is sufficient for most patients.
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Implications for practice and implications for research
The findings of this research indicate that 3 months of adjuvant chemotherapy may be sufficient for some
patients. For patients with low-risk stage III disease (T1–3, N1) receiving adjuvant oxaliplatin and capecitabine
chemotherapy, 3 months of treatment is sufficient. Many low-risk stage III patients receiving adjuvant
oxaliplatin and 5FU chemotherapy and high-risk stage III patients receiving adjuvant oxaliplatin and
capecitabine chemotherapy may be considered for 3 months of treatment. The optimum duration of
adjuvant treatment for high-risk stage III patients is less certain.
Research is needed on the influence of T4 or N2 on the required duration of adjuvant treatment for
high-risk stage III patients.
Further research should be conducted to identify any specific patient groups (e.g. patients with specific
high-risk pathological features) for whom 6 months of adjuvant chemotherapy might be appropriate and
if this is dependent on the regimen selected. The translational tissue samples from the SCOT study
(3383 tumour samples and 3100 blood samples) and from other similar studies should be used to build
molecular predictors of which patients may benefit from longer treatment. Some of this work is currently
under way for the SCOT study.
CONCLUSIONS
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Appendix 1 Baseline characteristics of
analysis subgroups
TABLE 15 Characteristics of patients assessed with NCI CTC AE
Characteristic
Randomised treatment group
3 months of treatment 6 months of treatment
Gender, n (%)
Female 166 (38.2) 165 (38.0)
Male 268 (61.8) 269 (62.0)
Total 434 (100) 434 (100)
Age at registration
Median (years) 63 65
IQR (years) 59–69 58–70
Range (years) 27–83 20–78
Total (n) 434 434
Performance status at randomisation, n (%)
0 276 (63.6) 263 (60.6)
1 158 (36.4) 171 (39.4)
Total 434 (100.0) 434 (100.0)
Disease site, n (%)
Colon 354 (81.6) 355 (81.8)
Rectum 80 (18.4) 79 (18.2)
Total 434 (100.0) 434 (100.0)
T stage, n (%)
0 0 (0.0) 1 (0.2)
1 11 (2.5) 10 (2.3)
2 43 (9.9) 39 (9.0)
3 246 (56.7) 250 (57.6)
4 134 (30.9) 134 (30.9)
Total 434 (100.0) 434 (100.0)
N stage, n (%)
0 58 (13.4) 56 (12.9)
1 250 (57.6) 255 (58.8)
2 126 (29.0) 123 (28.3)
Total 434 (100.0) 434 (100.0)
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TABLE 15 Characteristics of patients assessed with NCI CTC AE (continued )
Characteristic
Randomised treatment group
3 months of treatment 6 months of treatment
Planned treatment, n (%)
FOLFOX 155 (35.7) 158 (36.4)
CAPOX 279 (64.3) 276 (63.6)
Total 434 (100.0) 434 (100.0)
If CAPOX planned, starting dose of capecitabine, n (%)
750mg/m2 5 (27.8) 5 (22.7)
800 mg/m2 0 (0.0) 0 (0.0)
1000mg/m2 13 (72.2) 17 (77.3)
Total 18 (100.0) 22 (100.0)
High-risk stage II, n (%)
No 377 (86.9) 378 (87.1)
Yes 57 (13.1) 56 (12.9)
Total 434 (100.0) 434 (100.0)
CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU.
Reproduced from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
TABLE 16 Characteristics of patients assessed with EQ-5D
Characteristic
Randomised treatment group
3 months of treatment 6 months of treatment
Gender, n (%)
Female 361 (39.4) 363 (39.8)
Male 555 (60.6) 549 (60.2)
Total 916 (100.0) 912 (100.0)
Age at registration
Median (years) 64 65
IQR (years) 59–70 59–70
Range (years) 24–83 20–83
Total (n) 916 912
Performance status at randomisation, n (%)
0 595 (65.0) 581 (63.7)
1 321 (35.0) 331 (36.3)
Total 916 (100.0) 912 (100.0)
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TABLE 16 Characteristics of patients assessed with EQ-5D (continued )
Characteristic
Randomised treatment group
3 months of treatment 6 months of treatment
Disease site, n (%)
Colon 755 (82.4) 750 (82.2)
Rectum 161 (17.6) 162 (17.8)
Total 916 (100.0) 912 (100.0)
T stage, n (%)
0 0 (0.0) 1 (0.1)
1 22 (2.4) 25 (2.7)
2 84 (9.2) 80 (8.8)
3 527 (57.5) 516 (56.6)
4 282 (30.8) 290 (31.8)
X 1 (0.1) 0 (0.0)
Total 916 (100.0) 912 (100.0)
N stage, n (%)
0 140 (15.3) 141 (15.5)
1 519 (56.7) 517 (56.7)
2 257 (28.1) 254 (27.9)
Total 916 (100.0) 912 (100.0)
Planned treatment, n (%)
FOLFOX 292 (31.9) 297 (32.6)
CAPOX 624 (68.1) 615 (67.4)
Total 916 (100.0) 912 (100.0)
If CAPOX planned, starting dose of capecitabine, n (%)
750mg/m2 84 (22.3) 83 (22.4)
800 mg/m2 18 (4.8) 18 (4.9)
1000mg/m2 274 (72.9) 270 (72.8)
Total 376 (100.0) 371 (100.0)
High-risk stage II, n (%)
No 778 (84.9) 774 (84.9)
Yes 138 (15.1) 138 (15.1)
Total 916 (100.0) 912 (100.0)
CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU.
Reproduced from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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TABLE 17 Characteristics of patients assessed with EORTC QLQ-C30/CR29
Characteristic
Randomised treatment group
3 months of treatment 6 months of treatment
Gender, n (%)
Female 361 (39.4) 363 (39.8)
Male 555 (60.6) 550 (60.2)
Total 916 (100.0) 913 (100.0)
Age at registration
Median (years) 64 65
IQR (years) 59–70 59–70
Range (years) 24–83 30–83
Total (n) 916 913
Performance status at randomisation, n (%)
0 595 (65.0) 582 (63.7)
1 321 (35.0) 331 (36.3)
Total 916 (100.0) 913 (100.0)
Disease site, n (%)
Colon 755 (82.4) 751 (82.3)
Rectum 161 (17.6) 162 (17.7)
Total 916 (100.0) 913 (100.0)
T stage, n (%)
0 0 (0.0) 1 (0.1)
1 22 (2.4) 25 (2.7)
2 84 (9.2) 80 (8.8)
3 527 (57.5) 517 (56.6)
4 282 (30.8) 290 (31.8)
X 1 (0.1) 0 (0.0)
Total 916 (100.0) 913 (100.0)
N stage, n (%)
0 140 (15.3) 141 (15.4)
1 519 (56.7) 518 (56.7)
2 257 (28.1) 254 (27.8)
Total 916 (100.0) 913 (100.0)
Planned treatment, n (%)
FOLFOX 292 (31.9) 297 (32.5)
CAPOX 624 (68.1) 616 (67.5)
Total 916 (100.0) 913 (100.0)
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TABLE 17 Characteristics of patients assessed with EORTC QLQ-C30/CR29 (continued )
Characteristic
Randomised treatment group
3 months of treatment 6 months of treatment
If CAPOX planned, starting dose of capecitabine, n (%)
750mg/m2 84 (22.3) 84 (22.6)
800 mg/m2 18 (4.8) 18 (4.8)
1000mg/m2 274 (72.9) 270 (72.6)
Total 376 (100.0) 372 (100.0)
High-risk stage II, n (%)
No 778 (84.9) 775 (84.9)
Yes 138 (15.1) 138 (15.1)
Total 916 (100.0) 913 (100.0)
CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU.
Reproduced from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
4.0 license (https://creativecommons.org/licenses/by/4.0/).
TABLE 18 Characteristics of patients assessed with GOG-Ntx4
Characteristic
Randomised treatment group
3 months of treatment 6 months of treatment
Gender, n (%)
Female 562 (38.9) 548 (38.4)
Male 883 (61.1) 878 (61.6)
Total 1445 (100.0) 1426 (100.0)
Age
Median (years) 64 65
IQR (years) 58–70 59–70
Range (years) 24–83 20–85
Total (n) 1445 1426
Performance status at randomisation, n (%)
0 993 (68.7) 965 (67.7)
1 452 (31.3) 461 (32.3)
Total 1445 (100.0) 1426 (100.0)
Disease site, n (%)
Colon 1169 (80.9) 1155 (81.0)
Rectum 276 (19.1) 271 (19.0)
Total 1445 (100.0) 1426 (100.0)
continued
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TABLE 18 Characteristics of patients assessed with GOG-Ntx4 (continued )
Characteristic
Randomised treatment group
3 months of treatment 6 months of treatment
T stage, n (%)
0 0 (0.0) 1 (0.1)
1 35 (2.4) 42 (2.9)
2 133 (9.2) 126 (8.8)
3 831 (57.5) 806 (56.5)
4 445 (30.8) 451 (31.6)
X 1 (0.1) 0 (0.0)
Total 1445 (100.0) 1426 (100.0)
N stage, n (%)
0 232 (16.1) 230 (16.1)
1 830 (57.4) 816 (57.2)
2 383 (26.5) 380 (26.6)
Total 1445 (100.0) 1426 (100.0)
Planned treatment, n (%)
FOLFOX 467 (32.3) 458 (32.1)
CAPOX 978 (67.7) 968 (67.9)
Total 1445 (100.0) 1426 (100.0)
If CAPOX planned, starting dose of capecitabine, n (%)
750mg/m2 159 (21.8) 149 (20.6)
800 mg/m2 28 (3.8) 30 (4.1)
1000mg/m2 543 (74.4) 545 (75.3)
Total 730 (100.0) 724 (100.0)
High-risk stage II
No 1215 (84.1) 1199 (84.1)
Yes 230 (15.9) 227 (15.9)
Total 1445 (100.0) 1426 (100.0)
CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU.
Reproduced from Iveson et al.16 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the
CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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Appendix 2 Reasons for missing quality of life
questionnaires, examination of pattern of missingness
and sensitivity analysis
I t can be seen that the reasons are broadly similar between the treatment groups, the most commonreason being ‘other’. Examination of a random sample of the free text on the CRFs when the reason for
‘other’ was entered indicates that in the vast majority of cases this was an error of some sort (e.g. form
was not returned, a site error occurred, patient forgot). The high proportion of ‘not required’ for GOG-Ntx4
is a result of administrative delay in implementing the amendment to extend the recording period for
the questionnaire.
TABLE 19 Reasons for missing questionnaires as recorded on study CRF
Missing questionnaires: reason
Treatment group
3 months 6 months
EORTC questionnaire, n (%)
Complete 6629 (81.4) 7420 (80.2)
Patient refused 175 (2.1) 168 (1.8)
Patient relapsed/evidence of new tumour 56 (0.7) 53 (0.6)
Patient unfit 33 (0.4) 46 (0.5)
Other 1233 (15.1) 1542 (16.7)
Not required 19 (0.2) 28 (0.3)
EQ-5D questionnaire, n (%)
Complete 8924 (76.2) 9684 (75.3)
Patient refused 256 (2.2) 273 (2.1)
Patient relapsed/evidence of new tumour 213 (1.8) 181 (1.4)
Patient unfit 73 (0.6) 89 (0.7)
Other 2204 (18.8) 2573 (20.0)
Not required 46 (0.4) 55 (0.4)
GOG-Ntx4 questionnaire, n (%)
Complete 9658 (64.4) 10,858 (65.6)
Patient refused 263 (1.8) 281 (1.7)
Patient relapsed/evidence of new tumour 190 (1.3) 187 (1.1)
Patient unfit 74 (0.5) 101 (0.6)
Other 2890 (19.3) 3255 (19.7)
Not required 1924 (12.8) 1871 (11.3)
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Table 20 shows the proportion of missing PRO questionnaires by baseline patient characteristics. It can be
seen that the proportion is very similar for all baseline characteristics, with the difference in general being
very small and never exceeding 5%.
Table 21 summarises the comparison of the three most important PRO end points at key time points. The
first column is taken from the imputation analysis as presented in the paper, the second column is based
on observed data and the last column is based on an imputation restricted to patients who completed a
baseline questionnaire. This last analysis was carried out to ensure that the analysis set could not be influenced
by a patient's subsequent experience on the study (e.g. patients who should have completed at baseline
but were missed and subsequently completed a follow-up form because they developed neurotoxicity are
omitted from this analysis).
At all time points the mean differences are similar and consistent in terms of statistical significance.
TABLE 20 Missing questionnaires (yes/no) by baseline characteristics
Characteristic
EORTC missing, n (%) EQ-5D missing, n (%) GOG-Ntx4 missing, n (%)
No Yes No Yes No Yes
Gender
Female 5371 (79.8) 1362 (20.2) 7103 (74.9) 2376 (25.1) 7753 (64.4) 4286 (35.6)
Male 8678 (81.3) 1991 (18.7) 11,505 (76.2) 3587 (23.8) 12,763 (65.4) 6750 (34.6)
Age group (years)
≤ 50 1326 (81.3) 304 (18.7) 1715 (75.1) 570 (24.9) 1940 (65.4) 1026 (34.6)
≤ 70 9529 (80.9) 2250 (19.1) 12,666 (76.2) 3958 (23.8) 13,961 (65.0) 7503 (35.0)
> 70 3194 (80.0) 799 (20.0) 4227 (74.7) 1435 (25.3) 4615 (64.8) 2507 (35.2)
Performance status
0 9259 (80.6) 2222 (19.4) 12,190 (75.4) 3980 (24.6) 14,112 (65.4) 7451 (34.6)
1 4790 (80.9) 1131 (19.1) 6418 (76.4) 1983 (23.6) 6404 (64.1) 3585 (35.9)
T-stage
X/0/1 406 (77.3) 119 (22.7) 536 (74.5) 183 (25.5) 583 (63.9) 330 (36.1)
2 1278 (81.2) 296 (18.8) 1710 (76.8) 518 (23.2) 1888 (65.6) 991 (34.4)
3 8082 (81.7) 1811 (18.3) 10,783 (76.8) 3250 (23.2) 11,866 (65.7) 6200 (34.3)
4 4283 (79.2) 1127 (20.8) 5579 (73.5) 2012 (26.5) 6179 (63.7) 3515 (36.3)
N-stage
0 2121 (82.5) 451 (17.5) 3072 (77.2) 908 (22.8) 3566 (66.3) 1810 (33.7)
1 8004 (81.1) 1863 (18.9) 10,514 (76.2) 3287 (23.8) 11,724 (65.5) 6172 (34.5)
2 3924 (79.1) 1039 (20.9) 5022 (74.0) 1768 (26.0) 5226 (63.1) 3054 (36.9)
Treatment
FOLFOX 5479 (82.1) 1197 (17.9) 6935 (76.8) 2090 (23.2) 7897 (67.7) 3765 (32.3)
CAPOX 8570 (79.9) 2156 (20.1) 11,673 (75.1) 3873 (24.9) 12,619 (63.4) 7271 (36.6)
CAPOX, oxaliplatin and capecitabine; FOLFOX, oxaliplatin and 5FU.
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TABLE 21 Sensitivity analysis of PRO results
Difference
Imputed (as in manuscript),
mean (SE)
Observed data only,
mean (SE)
Imputed (restricted to
patients who completed
baseline questionnaire),
mean (SE)
GOG-Ntx4 questionnaire
Differencea at 6 months –1.99 (0.17)b –2.31 (0.35)b –2.16 (0.28)b
Difference at 12 months –2.48 (0.15)b –2.54 (0.23)b –2.30 (0.20)b
Difference at 5 years –2.07 (0.33)b –1.90 (0.42)b –1.90 (0.34)b
EORTC-QLQ-C30 global quality of life
Difference at 6 months 11.58 (1.00)b 12.00 (1.41)b 12.72 (1.82)b
Difference at 12 months 1.48 (0.85)c 1.57 (0.99)c 1.22 (0.86)c
EQ-5D Visual Analogue Scale
Difference at 6 months 9.80 (1.04)b 7.05 (1.52)b 7.36 (0.90)b
Difference at 12 months 1.45 (0.88)c 1.68 (0.96)c 1.31 (1.00)c
a Difference at 3–6 months.
b p < 0.001.
c p > 0.05.
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Appendix 3 Short Course Oncology Therapy site
recruitment and principal investigators
Site name Principal investigator(s) Total recruitment (n)
Beatson West of Scotland Cancer Centre Professor Jim Cassidy 141
Dr Ashita Waterson
Royal United Hospital Bath Dr Gareth Rees 111
Dr Louise Medley
Dr Emma De Winton
Addenbrookes Hospital Dr Charles Wilson 97
Royal Cornwall Hospital Dr Richard Ellis 94
Royal Surrey County Hospital Dr Gary Middleton 93
Dr Sharadah Essapen
Castle Hill Hospital Dr Amandeep Dhadda 91
Mount Vernon Hospital Dr Rob Hughes 89
Bristol Oncology Centre Dr Stephen Falk 85
Queen’s Hospital Dr Sherif Raouf 83
Southampton General Hospital Dr Timothy Iveson 81
Western General Hospital Dr Lesley Dawson 80
Christie Hospital NHS Trust Dr Mark Saunders 77
Salisbury District Hospital Dr Timothy Iveson 77
Dr Alaaeldin Shablak
Velindre NHS Trust Hospital Dr Alison Brewster 76
St Bartholomews Hospital Dr David Propper 74
Queen Alexandra Hospital Dr Ann O’Callaghan 73
Sjællands Universites Hospital, Næstved Dr Neils Henrik Holländer 70
Princess Alexandra Hospital Dr John Bridgewater 69
Royal Marsden Hospital (Sutton) Professor David Cunningham 67
Leicester Royal Infirmary Professor Will Steward 59
Professor Anne Thomas
Worcester Royal Hospital Dr David Farrugia 59
Dr Mark Churn
Singleton Hospital Professor John Wagstaff 57
Birmingham Heartlands Hospital Dr Ian Geh 55
Dr Shobhit Baijal
Maidstone and Tunbridge Wells NHS Trust Dr Mark Hill 55
Royal Shrewsbury Hospitals NHS Trust Dr Saif Awwad 54
Dr Abel Zachariah
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Site name Principal investigator(s) Total recruitment (n)
Northampton General Hospital NHS Trust Dr Kinnari Patel 53
Dr Craig Macmillan
Dr Roshan Agarwal
Russells Hall Hospital Professor David Ferry 51
Dr Simon Grumett
Lincoln County Hospital Dr Tom Sheehan 50
Dr Zuzana Stokes
Fife Health Board Dr Catriona Mclean 48
King Edward VII Hospital Dr Marcia Hall 48
Dr Maher Hadaki
Royal Hampshire County Hospital Dr Virginia Hall 48
Dr Sanjay Raj
Dr David Nolan
Sunderland Royal Hospital Dr Ashraf Azzabi 48
West Suffolk Hospital Dr Anne Margaret Moody 48
Hammersmith Hospital Dr Charles Lowdell 47
Churchill Hospital Dr Andrew Weaver 46
Aarhus University Hospital Dr René Krøjgaard Olesen 45
Yeovil District Hospital Dr Stephen Falk 43
Dr Julie Walther
Dr Erica Beaumont
Dr Matthew Sephton
Kettering General Hospital Dr Craig Macmillan 42
Dr Guy Faust
Dr Roshan Agarwal
Crosshouse Hospital Dr Jeffery White 41
Musgrove Park Hospital Dr Julie Walther 41
Dr Clare Barlow
Worthing Hospital Dr Andrew Webb 41
Hinchingbrooke Hospital Dr Cheryl Palmer 40
Great Western Hospital Dr Claire Hobbs 39
Dr Sarah Lowndes
Hospital Universitari Vall D Hebron Dr Elena Elez Meelez 39
Monklands District General Hospital Dr Ashita Waterston 39
Dr Clinton Ali
Dr Anne Mckillop
Wycombe Hospital Dr Andrew Weaver 39
Aalborg Hospital Dr Jorgen Hansen 38
Dr Mette Yilmaz
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Site name Principal investigator(s) Total recruitment (n)
Ipswich Hospital Dr Rubin Soomal 38
Dr Liz Sherwin
Pilgrim Hospital Dr Tom Sheehan 38
Dr Zuzana Stokes
Raigmore Hospital Dr David Whillis 38
Dr Neil Mcphail
St James’s University Hospital Dr Daniel Swinson 38
Stepping Hill Hospital Dr Jurjees Hasan 38
Weston Park Hospital NHS Trust Dr Simon Pledge 38
Withybush General Hospital Dr Vallipuram Vigneswaran 38
Belfast City Hospital Dr Richard Wilson 37
Glan Clwyd Hospital Dr Simon Gollins 37
Guy’s and St Thomas’ NHS Trust Dr Nicholas Maisey 37
Poole Hospital NHS Trust Dr Tamas Hickish 37
Dr Amelie Harle
Royal Bournemouth Hospital Dr Tamas Hickish 37
Wrexham Maelor Hospital Dr Simon Gollins 37
Hillerød Hospital Dr Svend Erik Nielsen 36
Queen Elizabeth Hospital – King’s Lynn Dr Athar Ahmad 36
Dr Gail Horan
St George’s Hospital Dr Fiona Lofts 36
University College London Hospital Dr John Bridgewater 36
York Hospital Dr Kim Last 36
Nottingham University Hospital NHS Trust Dr Eric Bessell 35
Dr Vanessa Potter
Dr Georgina Walker
Royal Berkshire Hospital Dr James Gildersleve 35
Wexham Park Hospital Dr Marcia Hall 35
Dr Maher Hadaki
South Tyneside District Hospital Dr Shraf Azzabi 34
Broomfield Hospital Professor Saad Tahir 33
Dr Gopalakrishnan Srinivasan
Eastbourne District General Dr Fiona Mckinna 33
ICO L’Hospitalet Dr Ramon Salazar 33
Dr Gemma Soler
Torbay Hospital Dr Nangi Lo 33
Conquest Hospital Dr Timothy Sevitt 32
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Site name Principal investigator(s) Total recruitment (n)
Luton and Dunstable Hospital Dr Suzannah Mawdsley 32
Dr Faye Lim
Professor Peter Hoskin
Aberdeen Royal Infirmary Dr Leslie Samuel 31
Basingstoke and North Hampshire Hospital Dr Charlotte Rees 31
North Middlesex University Hospital Dr John Bridgewater 31
Queen’s Hospital Burton Dr Prabir Chakraborti 31
Dr Pugazhenthi Pattu
Dr Majusha Keni
Blackpool Victoria Hospital Dr Shabbir Susnerwala 30
Dr Sin Chong Lau
Cheltenham General Hospital Dr David Farrugia 30
Regionshospitalet Herning Dr Nina Keldsen 30
Diana Princess of Wales Hospital Dr Rajarshi Roy 29
Dorset County Hospital Dr Richard Osborne 29
Dr Maxine Flubacher
Cumberland Infirmary Dr Jonathan J Nicoll 28
Gloucestershire Royal Hospital Dr David Farrugia 28
Hereford County Hospital Dr Nick Reed 28
Rigshospitalet Dr Lone Nørgaard 28
Wansbeck Hospital Dr Werner Dobrowsky 28
Dr Sandeep Singhal
Charing Cross Hospital Dr Charles Lowdell 27
Dr Susan Cleator
Peterborough Hospital Dr Karen Mcadam 27
Dr Abigail Hollingdale
Queen Elizabeth Hospital (Gateshead) Dr Werner Dobrowsky 27
Dr Fiona McDonald
Dr Mark Katory
Queen Elizabeth Hospital (Birmingham) Dr Neil Steven 27
Scarborough Hospital Dr Mohan Hingorani 27
Dr Pugazhenthi Pattu
Southend Hospital Dr David Tsang 27
James Cook University Hospital Dr Nicholas Wadd 27
Altnagelvin Hospital Dr Russell Houston 26
Dr Claire Harrison
Dr Sonali Dasgupta
Scunthorpe General Hospital Dr Abdel Hamid 26
Dr Lorcan O’Toole
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Site name Principal investigator(s) Total recruitment (n)
Good Hope Hospital Dr John Glaholm 25
Dr Shobhit Baijal
Royal Sussex County Hospital Dr Andrew Webb 25
Hospital Donostia Dr Adelaida-Lacasta Munoa 24
New Cross Hospital Dr Mark Churn 24
Dr Simon Grummet
University Hospital of North Staffordshire Dr Fawzi Adab 24
Countess of Chester Hospital Dr Adrian Moss 23
Dr Shaker Abdallah
Dr Dale Vimalachandran
University Hospital of Lewisham Professor George Mikhael 23
Dr Jessica Brady
Royal Derby Hospital Dr Rajendra Kulkarni 23
Medway Maritime Hospital Dr Jeff Summers 22
Dr Christos Mikropoulos
Royal Preston Hospital Dr Shabbir Susnerwala 22
Dr Deborah Williamson
University Hospital of North Durham Dr Fareeda Coxon 22
Complejo Hospitalario Universitario de Santiago Dr Rafael Lopez 21
Forth Valley Royal Hospital Dr Ghazia Shaikh 21
Dr Saranya Kakumanu
Dr Stephen Harrow
Dr Adnan Shaukat
Dr Aisha Tufail
Dr Dawn Storey
Kent and Canterbury Hospital Professor Roger James 21
Dr Julia Hall
Dr Rakesh Raman
Basildon Hospital Dr David Tsang 20
Clatterbridge Centre for Oncology Dr David Smith 20
Dr Julie O’Hagan
Freeman Hospital Dr Fareeda Coxon 20
Stoke Mandeville Hospital Dr Andrew Weaver 20
Darlington Memorial Hospital Dr Fareeda Coxon 19
Harrogate District Hospital Dr Kim Last 19
Hospital Del Mar Dr Joaquim Bellmunt 19
Queen Elizabeth Hospital (London) Dr Nicholas Maisey 19
Dr Asad Qureshi
Royal Marsden Hospital (London) Professor David Cunningham 19
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Site name Principal investigator(s) Total recruitment (n)
Sjællands Universites Hospital, Roskilde Dr Jim Stenfatt Larsen 19
St Helens and Knowsley NHS Trust Dr Ernest Marshall 19
Karolinska University Hospital Dr Gisela Naucler 18
Dr Jan-Erik Frödin
Lister Hospital Dr Rob Hughes 18
St Mary’s Hospital (Low) Dr Christopher Baughan 18
Dr Harish Reddy
Glangwili General Hospital Dr Margaret Wilkins 18
Dr Thi Mau-Don Phan
William Harvey Hospital Professor Roger James 18
Dr Julia Hall
Bronglais General Hospital Dr Alan Axford 17
Dr Sajid Durrani
Dr Elin Jones
Darent Valley Hospital Dr Andrew Gaya 17
Dr Hazif Al Gurafi
Dr Riyaz Nazeerul Haq Shah
Hairmyres Hospital Dr Grainne Dunn 17
Kidderminster Hospital Dr Mark Churn 17
The Royal Oldham Hospital Dr Saifee Mullamitha 17
Ayr Hospital Dr Jeffery White 16
Craigavon Area Hospital Dr Richard Park 16
Esbjerg Hospital Dr Brita Bjerregaard 16
King’s Mill Hospital Dr Ivo Hennig 16
Dr Eleanor James
Dr Eliot Chadwick
Dr Christina Lopezesccola
Warrington and Halton Hospitals NHS Trust Dr Adrian Moss 16
Dr Amy Ford
Herlev Hospital Dr Kirsten Vistisen 15
Hospital Arnau De Villanova Lleida Dr Antonia Salud 15
Macclesfield District General Hospital Dr Catherine Mcbain 15
Dr Ganesh Radhakrishna
Bradford Royal Infirmary Dr Chris Bradley 14
Dr Andrew Conn
North West London Hospitals NHS Trust Dr Nicola Anyamene 14
Royal Free Hospital Dr Astrid Mayer 14
Sønderborg Hospital Dr Jurij Bogovic 14
University Hospital of North Tees Dr David Wilson 14
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Site name Principal investigator(s) Total recruitment (n)
Bendigo Hospital Dr Robert Blum 13
Bishop Auckland General Hospital Dr Nick Wadd 13
Dr Fareeda Coxon
Central Hospital Vasteras Dr Henry Letocha 13
Dr Andrzej Piwowar
City Hospital Trust Dr Daniel Rea 13
Dr Pankaj Punia
Manor Hospital Dr Andrew Hartley 13
Dr Victoria Kunene
Royal Hobart Hospital Dr Ray Lowenthal 13
Dr David Boadle
Royal Albert Edward Infirmary Dr Gregory Wilson 13
Dr Elena Takeuchi
Dr Francisca Elena Marti
Weston General Hospital Dr Marjorie Tomlinson 13
Dr Reuben West
Austin Hospital Dr Niall Tebbutt 12
Bankstown – Lidcombe Hospital Dr Ray Asghari 12
Nambour General Hospital Dr Michelle Cronk 12
Queen Elizabeth The Queen Mother Hospital Professor Roger James 12
Dr Julia Hall
Bedford Hospital NHS Trust Professor Robert Thomas 11
Hospital Universitario De Canarias Dr Marta Llanos 11
Hospital Clinico Universitario De Valencia Dr Andres Cervantes 11
Royal Marsden Hospital (Kingston) Dr David Cunningham 11
Uppsala University Hospital Dr Bengt Glimelius 11
West Cumberland Hospital Dr Jonathan J Nicoll 11
West Middlesex University Hospitals Dr Pippa Riddle 11
Hospital Clinic I Provincial De Barcelona Dr Cristina Nadal 10
Dr Estela Pineda
North Devon District Hospital Dr Mark Napier 10
Sandwell General Hospital Dr Daniel Rea 10
Dr Pankaj Punia
Southport and Formby District General Hospital Dr Arthur Sun Myint 10
Dr Nasim Ali
St Mary’s Hospital London Dr Susan Cleator 10
The Tweed Hospital Professor Ehtesham Abdi 10
Ysbyty Gwynedd Hospital Dr Nick Stuart 10
Dr Catherine Bale
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Site name Principal investigator(s) Total recruitment (n)
Ballarat Hospital Dr Geoff Chong 9
Canberra Hospital Professor Desmond Yip 9
Centrallasarettet Vaxjo Dr Eva Fernebro 9
Dr Ulrika Palenius
Complejo Hospitalario Universitario De Albacete Dr Carmen Alonso Lopez 9
Hospital Universitario Marques De Valdecilla Dr Fernando Rivera-Herrero 9
St John of God Hospital Bunbury Dr Martin Buck 9
Airedale General Hospital Dr Andrew Conn 8
Aintree University Hospitals Dr David Smith 8
Dr Julie Hagan
Alfred Hospital Dr Andrew Haydon 8
Auckland Hospital Dr George Laking 8
Concord Repatriation General Hospital Professor Philip Beale 8
Flinders Medical Centre Dr Chris Karapetis 8
Hospital Universitario Madrid Norte Sanchinarro Dr Antonio Cubillo 8
North Tyneside General Hospital Dr Philip Atherton 8
Royal Devon and Exeter Hospital Dr Melanie Osborne 8
Dr Mark Napier
County Hospital Ryhov Dr Helga Hagman 7
Hospital La Fe Dr Jorge Aparicio 7
Hospital Virgen De La Arrixaca Dr Miguel Marin Vera 7
Inverclyde Royal Hospital Dr Stephen Harrow 7
Dr Dawn Storey
Royal Lancaster Infirmary Dr David Fyfe 7
Dr David Eaton
Royal Brisbane and Women’s Hospital Dr Matthew Burge 7
Whittington Hospital Dr Daniel Hochhauser 7
Dr Pauline Leonard
University Hospital of Hartlepool Dr David Wilson 7
University Hospital Linköping Dr Maria Albertsson 7
Cabrini Hospital Dr Andrew Haydon 6
Calderdale and Huddersfield NHS Foundation Trust Dr Jo Dent 6
Dumfries and Galloway Royal Infirmary Dr Lesley Dawson 6
Hospital Miguel Servet Dr Antonio Anton 6
Hospital De Txagorritxu Dr Severina Dominguez 6
Leighton Hospital Dr Chan Ton 6
Dr Michael Braun
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Site name Principal investigator(s) Total recruitment (n)
Milton Keynes General Hospital Dr Jill Stewart 6
Dr Gerard Andrade
Dr Somnath Mukherjee
Prince of Wales Hospital Professor David Goldstein 6
Queen Elizabeth Hospital (Australia) Professor Tim Price 6
Royal North Shore Hospital Dr Alex Guminski 6
Associate Professor Nick Pavlakis
St Vincent’s Hospital Dr Eva Segelov 6
Essex County Hospital Dr Bruce Sizer 5
Falu Hospital Dr Ake Berglund 5
Pinderfields General Hospital Dr Gireesh Kumaran 5
Dr Konstantinos Kamposioras
Campbelltown Hospital Dr Lorraine Chantrill 4
Christchurch Hospital Dr Mark Jeffery 4
Furness General Hospital Dr Alison Birtle 4
Dr David Eaton
Illawarra Cancer Centre (Wollongong Hospital) Dr Morteza Aghmesheh 4
Kalmar County Hospital Dr Charlotte Bratthall 4
Nevil Hall Hospital Dr Nayyer Iqbal 4
Dr Mohammed Harb
Dr Keith Yinn
Nepean Cancer Care Centre Dr Jenny Shannon 4
Norrlands University Hospital Dr Birgitta Lindh 4
Princess Alexandra Hospital (Australia) Dr Warren Joubert 4
Royal Darwin Hospital Dr Narayan Karanth 4
St John of God Hospital Subiaco Dr Siobhan Ng 4
Dr Tom Van Hagen
Tamworth Base Hospital Dr Mathew George 4
Antrim Area Hospital Dr Colin Purcell 3
St Richard’s Hospital Dr Suhail Baluch 3
Dr Ann O’Callaghan
Dr Yasser Haba
Wellington Hospital Dr Anne O’Donnell 3
Ballarat Oncology and Haematology Services Dr George Kannourakis 2
Coffs Harbour Health Campus Dr Karen Briscoe 2
Gosford Hospital Dr Susan Tiley 2
Hallands Hospital Dr Lotta Lundgren 2
Royal Perth Hospital Dr David Ransom 2
University Hospital of Skåne Dr Margareta Heby 2
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Site name Principal investigator(s) Total recruitment (n)
Armidale Hospital Associate Professor Nick Pavlakis 1
Dunedin Hospital Dr Chris Jackson 1
Hospital De Cruces Dr Guillermo Lopez Vivanco 1
ICO Del Hospital Josep Trueta Dr Bernardo Queralt 1
Royal Liverpool University Hospital Dr David Smith 1
Sundsvall Härnösand County Hospital Dr Petra Flygare 1
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